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Summary 
The accumulation of misfolded proteins into insoluble aggregates is a common feature in a 
variety of neurodegenerative diseases, and it is thought that the aggregation process plays 
a central role in the pathogenesis. Parkinson´s disease (PD) is the most common move-
ment disorder and characterized by a progressive and selective degeneration of dopamin-
ergic neurons of the substantia nigra. Histopathologically, the hallmark feature of PD is the 
intracellular deposition of aggregated α-synuclein (αS) protein in Lewy bodies. In PD pa-
tients, Lewy pathology occurs in a stereotypic pattern, originating in lower brain regions 
before spreading to higher areas of the brain. Despite a significant amount of research, the 
mechanism underlying the formation of αS lesions is still poorly understood. However, 
recent findings highlight that a nucleation-dependent aggregation mechanism, initially de-
scribed for prion diseases may also contribute to the propagation of protein aggregation in 
other neurodegenerative disorders. According to this concept, corrupted protein particles 
can act as nuclei (or ‘seeds’) of aggregation and further convert endogenous proteins into 
their pathological isoforms.  
The main objective of this thesis was to study the ‘prion-like’ properties of αS to gain fur-
ther insight into the pathogenesis of PD. In our studies we used different transgenic mouse 
models of synucleinopathy, which are based on mutations identified in human disease and 
replicate some aspects of the PD pathology, to probe this theoretical explanation of dis-
ease. These mouse lines harbor either the A53T (Tg-9813[A53T]αS and Tg-
M83[A53T]αS) or A30P human αS transgene (Tg-[A30P]αS). Tg-9813[A53T]αS mice de-
velop a severe and early-onset synucleinopathy. On the other hand, both Tg-
M83[A53T]αS and Tg-[A30P]αS mice (both being homozygous for the transgene) have a 
delayed-onset of motor symptoms, whereas the latter tend to exhibit a milder disease phe-
notype. As shown previously by other research groups, synucleinopathy can be induced 
by exogenous αS seeds in vivo. Accordingly, we performed a series of inoculation experi-
ments to investigate the seeding effect of pathological αS. 
In a first set of experiments, we assessed whether αS seeds were still capable of inducing 
fatal synucleinopathy when treated with formaldehyde. In a previous study, our lab had 
shown that Aβ seeds resist the inactivation by formaldehyde fixation similar to prions. 
Therefore, we intracerebrally inoculated young pre-symptomatic mice with extracts from 
formaldehyde-fixed and fresh-frozen brainstem tissue. Remarkably, in Tg-9813[A53T]αS 
mice we found that fixed αS seeds were able to induce synucleinopathy lesions after 30 
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days of incubation. Stimulated by these results, we repeated the experiment in Tg-
[A30P]αS mice and incubated until motor symptoms presented. Intriguingly, we found that 
the pathogenicity of αS seeds was retained even after formaldehyde fixation prior to the 
injection. Remarkably, the extract from formaldehyde-fixed brainstem tissue was almost as 
potent as the fresh-frozen tissue-derived extract with regard to both survival time and 
pathological αS load. 
The second part of this thesis was focused on investigating whether CSF from mice with 
synucleinopathy is seeding active. While our group and others had already shown that 
extracts from mouse brain tissue containing aggregated αS are potent inducers of synucle-
inopathy, it is still unclear if extracellular αS from a bodily fluid is also pathogenic. Our first 
results revealed an elevated level of αS in the CSF of symptomatic Tg-[A30P]αS mice. 
Therefore, we intracerebrally inoculated young presymptomatic Tg-[A30P]αS mice with 
CSF of spontaneously ill donors. To compare the putative seeding potential of CSF-
derived αS, we additionally performed intracerebral inoculations of the PBS-soluble and 
PBS-insoluble fractions of brainstem-derived extracts. Our results showed that CSF was 
not able to induce a synucleinopathy. Likewise, the PBS-soluble fraction failed to induce 
αS lesions in Tg-[A30P]αS mice, suggesting a lack of pathogenicity. Conversely, we found 
a severe induction of synucleinopathy lesions and a significantly reduced life span after 
inoculation with PBS-insoluble αS seeds in comparison to the non-tg control inoculum. 
Although less than 4% of the αS remained in this fraction, PBS-insoluble αS seeds were 
highly seeding-active when compared to the original extract that was diluted to match with 
the αS level of both the soluble and insoluble fractions. In addition, we found that the 
seeded induction of αS lesions occurred in a concentration-dependent manner. 
Finally, in a last set of experiments we have investigated the cross-seeding effect of two 
mutant αS pathogens, since in vitro studies have indicated that there are indications for 
structural and functional differences among fibrils of either the mutant A53T or A30P hu-
man αS. When injected into the hippocampus of young presymptomatic Tg-M83[A53T]αS 
and Tg-[A30P]αS mice, we found that both extracts induced an accelerated disease phe-
notype with reduced survival times. Moreover, we observed seeded synucleinopathy le-
sions in each of the recipient mouse strains. However, we found that both the incubation 
time and the pathology were not different between the tg extract-injected mice in either of 
the lines indicative of a strong host effect. Therefore, to determine whether the two αS 
extracts have a differential cross-seeding capacity, we injected hemizygous Tg-
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M83[A53T]αS and Tg-[A30P]αS mice that – uninoculated – remain healthy until late adult-
hood. Intriguingly, both extracts were capable of inducing a de novo synucleinopathy in 
both mouse strains. While we did not find a significant difference in the incubation periods 
between the two αS extracts in the hemizygous Tg-M83[A53T]αS mice, the A30P-derived 
extract was markedly more potent in reducing the survival time than A53T in hemizygous 
Tg-[A30P]αS mice. 
In summary, we were able to study the exogenous seeding mechanism of αS in different 
mouse models of synucleinopathy. Our data provide new insight into the persistent nature 
of αS seeds that is reminiscent of prions. Moreover, the results of this thesis indicate that 
PD-linked αS mutants may dictate functional characteristics in vivo. Thus, our findings 
support the concept that synucleinopathies share several common features with prion dis-
eases. Consequently, Insight into the seeding aspect of the disease could lead to a better 
understanding of the misfold initiation and spread of the pathogenic protein, ultimately pav-
ing the way to therapeutical strategies targeting this particular attribute of PD. 	
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1  Introduction 
1.1 Aging and disease 
The time-dependent decline in cellular fitness and the increase in mortality is what we 
commonly refer to as aging (López-Otín et al., 2013). Unlike any other organ of the human 
body, the brain possesses a very high vulnerability response to oxidative, metabolic, and 
ionic stress that cells experience during a lifetime. In individuals, the process of healthy 
aging does not necessarily occur synchronously in all cell types resulting in a disparity 
between physical and mental health. Since most of the neurons are post-mitotic cells (in 
contrast to other cell types), adapting to these changes is key to a healthy aging process. 
Despite relentless research dedicated to unraveling the molecular basis of aging, there 
has been no popularly accepted mechanism to describe senescence (Lenart and Krejci, 
2016). 
When neurons fail to adjust to age-dependent changes, the balance is likely to shift to a 
pathological state, where damaged proteins and DNA accumulate inside and outside the 
cells, impairing cellular function and ultimately degenerate. Dementia represents a signifi-
cant part of the neural aging disorders. The irreversible degeneration of cells in the nerv-
ous system is the main disease characteristic, which clinically manifests in a progressive 
cognitive decline among affected individuals. The prevalence of developing dementia in-
creases dramatically with age. Whether or not a person subjects to a neurodegenerative 
disease is, however, not solely determined by the individual’s age, but is counteracted or 
contributed by environmental factors, their family history and genetic background. None-
theless, the overall prevalence of contracting a form of dementia is about 10% during a 
lifespan (Loy et al., 2014). 
The global average life expectancy has more than doubled since the beginning of the 20th 
century, which has lead to an overall aging of the population (Oeppen and Vaupel, 2002). 
As a result, the prevalence of neurodegenerative diseases has increased significantly, 
afflicting individuals across all segments of society and posing a challenge for health insti-
tutions worldwide. Therefore, the intended aims of current neuroscience research should 
be focused on understanding the molecular and cellular mechanisms underlying (brain) 
aging in health and disease.  
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1.2   Parkinson’s disease 
In 1817, James Parkinson published a clinical essay describing a wasting disorder affect-
ing the locomotor system of humans (“shaking palsy”) (Parkinson, 2002, Lees, 2007). 
Even though many before him had forestalled the topic, his clear clinical description 
helped to draw the attention of physicians worldwide to the illness that later would carry his 
name. Now, almost two hundred centuries later, Parkinson’s disease (PD) is known to be 
the second most common degenerative disease of the nervous system and the most 
common movement disorder affecting people all over the globe (Lesage and Brice, 2009). 
The clinical syndrome is characterized by a panoply of motor signs such as bradykinesia 
(i.e. slowness of voluntary movement), rigidity, resting tremor, and instability of gait, as 
well as non-motor symptoms like hyposmia, sleep disturbances, and depression that may 
affect the patient’s quality of life tremendously. Often, the non-motor phenotype precedes 
the motoric facet of the disease (Lang and Lozano, 1998a, 1998b). The average age of 
onset is between 50 and 70 years (de Rijk et al., 1995, de Laud and Breteler, 2006). The 
disease progresses slowly and terminates with death 10 to 20 years later. The prevalence 
of PD increases with advancing age from 1% to 2% to up to 4% to 5% in people above the 
age of 85 (de Rijk et al., 1995). The lifetime incidence of developing PD is 2% (Pringsheim 
et al., 2014). Worldwide, an estimated 7 million people are suffering from PD 
(www.pdf.org). The non-heritable idiopathic cases contrast the rare familial forms of PD 
(FPD), which are caused by single gene mutations and constituting less than 10% of all 
cases (Thomas et al., 2007). Molecular genetic analysis of these families has revealed 
mutations in more than 10 genes (Corti et al., 2011, Houlden and Singleton, 2012, Ferreira 
and Massano, 2016), whereas, the etiology of sporadic PD is far more complex with many 
factors contributing to the age of onset, disease progression and duration. 
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1.2.1   Neuropathology of Parkinson’s disease 
The neuropathology of PD is characterized by the progressive and selective loss of dopa-
minergic neurons in the substantia nigra pars compacta (SNc) of the midbrain (overviewed 
in Figure 1) associated with intracellular inclusions called Lewy bodies (LBs) and Lewy 
neurites (LNs) in surviving neurons (Gibb and Lees, 1988, Fearnley and Lees, 1991, Forno 
et al., 1996). LBs are round eosinophilic, proteinaceous deposits consisting primarily of 
filamentous α-synuclein (αS) aggregates, neurofilaments, and ubiquitin, and are consid-
ered to be a hallmark feature of neurodegeneration (Forno, 1996, Spillantini et al., 1997).  
                       
Figure 1. Corticostriatal pathway in Parkin-
son’s disease. Degeneration of the dopa-
minergic neurons (dashed lines) from the 
substantia nigra pars compacta (SNc) pro-
jecting to the striatum leads to a diminished 
inhibition of globus pallidus interna (direct 
pathway). Hence, thalamic excitation of the 
motor cortex is less likely. Changes are indi-
cated with red arrows (up: increase; down: 
decline). (After DeLong, 1990.) 
 
 
 
 
 
Apart from PD, LBs are the main pathological characteristic in at least two other neuro-
degenerative diseases, dementia with LB (DLB) and multiple system atrophy (MSA) that 
are collectively known as “synucleinopathies” (Spillantini et al., 1997, Spillantini et al., 1998, 
Goedert et al., 2013). In PD patients, αS deposition and LB pathology seems to occur in a 
stereotypic manner along interconnected neuronal pathways, making it possible to distin-
guish six stages of αS pathology (Braak et al., 2003, Braak et al., 2009). At first, deposition 
of αS occurs in the anterior olfactory nucleus and the dorsal motor nuclei of the vagal and 
glossopharyngeal nerves in the brainstem (stage 1). In stage 2, LBs and LNs are observed 
in the medulla oblongata and the pontine tegmentum. Then, the αS lesions spread to-
wards the amygdala and the SNc in the midbrain (stage 3). At this stage, usually the first 
motor symptoms begin to appear. By stage 4, the pathology has reached the temporal 
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mesocortex as the first cortical region. Finally, in the last two stages the pathology attain 
the neocortex including high order sensory association areas and areas of the premotor 
cortex (stages 5 and 6) (Braak et al., 2003, Braak et al., 2009). Conversely, there is 
emerging evidence suggesting an initiation of disease in the gastrointestinal tract including 
the autonomic nervous system and the enteric nervous system (Hawkes et al., 2007, 
Hawkes et al., 2009).  
At present, there is no cure for PD, and classic therapeutic approaches are rather limited 
to treating the disease symptoms than meeting the root of the illness (overviewed in Hick-
ey and Stacy, 2011). Notwithstanding the benefits of current therapies for thousands of 
patients, new therapeutic strategies should be aimed at modifying the course of the dis-
ease (reviewed in Eisele et al., 2015). Likewise, reliable diagnostic means need to be es-
tablished to determine PD at an early stage, where therapies are most effective. Therefore, 
it is of paramount importance to fully unravel and understand the etiology and pathogene-
sis of PD to open up new ways for novel, cause-directed therapies.  
 
1.2.2   The role of α-synuclein in PD 
Almost 100 years after James Parkinson had published his famous forward-looking clinical 
essay, Friedrich Heinrich Lewy described in 1912 the intracellular inclusions in both the 
cell bodies (i.e. LBs) and cell processes (i.e. LNs) of neurons (Lewy, 1912). Nonetheless, it 
was not until the late 1990s when two findings brought the focus of work on the pathogen-
esis of PD to the protein αS (see Fig. 2) (Polymeropoulos et al., 1997, Spillantini et al., 
1997). The identification of SNCA mutations led to the first direct link between genetics 
and LB pathology observed in hereditary as well as idiopathic PD (Polymeropoulos et al., 
1996, Polymeropoulos et al., 1997). The subsequent discovery of αS in LBs in the brains 
of sporadic PD patients further supported the role of the protein in the pathobiology of the 
disease (Spillantini et al., 1997). To date, a total of six point mutations in the αS gene have 
been identified to cause rare familial forms of PD (Polymeropoulos et al., 1997, Krüger et 
al, 1998, Zarranz et al., 2004, Appel-Cresswell et al., 2013, Proukakis et al., 2013, Lesage 
et al., 2013, Pasanen et al., 2014). By far the most frequent SNCA mutation in humans is 
the alanine-to-threonine substitution at codon 53 in the protein sequence (A53T) (Poly-
meropoulos et al., 1997). Apart from A53T, the alanine-to-proline substitution at position 
30 (A30P) has been known and studied for almost two decades (Krüger et al, 1998). Im-
portantly, duplications and triplications of wild-type (wt) SNCA also cause FPD (Chartier-
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Harlin et al., 2004, Singleton et al., 2003), whereas the multiplicity of the gene locus corre-
lates positively with the clinical manifestation of the disease suggesting a causal link be-
tween SNCA gene dosage and disease phenotype (Ibáñez et al, 2004). 
 
       
Figure 2. The structure of α-synuclein. The protein folds into two α-helices upon binding to lipid 
membranes conferred by seven imperfect 11-residue repeats (KTKEGVXXXX) that include the 
highly conserved KTKEGV consensus sequence (light gray boxes). The N-terminus (light green; 
amino acids 1 to 60) contains with five repeat sequences. The hydrophobic middle segment, i.e. 
non-amyloid-β component of AD amyloid (NAC), confers the propensity to fold into a β-sheet sec-
ondary structure (light orange; 61 to 95). The highly negatively charged C-terminal domain is not 
implicated in membrane binding and is intrinsically disordered (light blue; 96 to 140). Interestingly, 
all of the mutations associated with PD – A53T, A30P, E46K, H50Q, G51D, and A53E – lie within 
the N-terminal region. Conversely, the C-terminus contains the majority of post-translational modifi-
cations including phosphorylation at 4 residues (Tyr 125, Ser 129, Tyr 133, and Tyr 136). (Modified 
from  Breydo et al., 2012.) 
 
Besides its role in disease, αS has been implicated in various cellular processes (over-
viewed in Bendor et al, 2013). Nonetheless, the physiological function remains elusive. 
Therefore, over the last decade research has been focused particularly on elucidating the 
structure and function of this protein (for a review see Bennett, 2005).  
 
1.2.2.1   The amyloid state of α-synuclein 
The aggregation of misfolded proteins is a common feature of many neurodegenerative 
diseases, including αS in PD, the amyloid-β (Aβ) peptide in Alzheimer’s disease (AD) or 
the microtubule associated protein tau in frontotemporal dementia and AD (reviewed in 
Jucker and Walker, 2013). In fact, many such proteinopathies have been described so far 
(Bayer, 2013). In line with this, there is compelling evidence that αS aggregation is the 
critical step in the pathogenesis of PD and other synucleinopathies. The mechanism un-
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derlying protein aggregation is a multi-step process involving several off-pathway interme-
diate forms whose generation is given by their respective kinetics (Fig. 3).  
 
 
Figure 3. Mechanism of α-synuclein aggregation and fibrillogenesis. In a native state, αS appears 
to be present as an unfolded monomer in solution or in an α-helical conformation when bound to a 
membrane. Soluble oligomers of unfolded αS might thereby represent an on-pathway condition. On 
the other hand, the non-native aggregation of αS involves a misfolded intermediate that escapes 
the cellular clearance machinery and is prone to oligomerize into β-sheet rich protofibrils, which may 
give rise to more stable amyloid fibrils. Finally, the pathological aggregation results in the formation 
of the bulky, cytoplasmic inclusions seen as LBs. (Modified from Lashuel et al., 2013.) 
 
In vitro, natively unfolded αS monomers have a high intrinsic propensity to form fibrils. 
Thereby the formation of amyloid β-sheet structures involves a conformational transition 
(i.e. “misfolding”) of the protein (Uversky et al., 2001). Under physiological condition, there 
is an equilibrium state between the natively unfolded and the misfolded αS conformation. 
However, the misfolding of αS can be induced or inhibited by several intrinsic or extrinsic 
factors (reviewed in Uversky, 2007). For example, several different posttranslational modi-
fications have been thought to be important modifiers of protein aggregation (reviewed in 
Barrett, 2015). These modifications include phosphorylation, ubiquitination, oxidation, and 
nitration. Of note, αS phosphorylation appears to be significantly increased throughout 
synucleinopathy lesions (Fujiwara et al., 2002, Paleologou et al., 2010, Hejjaoui et al., 
2012). In fact, about 90% of the insoluble αS was found to be phosphorylated at Ser 129 
(pS129) making it a consistent marker of αS pathology (Fujiwara et al., 2002, Anderson et 
al., 2006). Likewise, sequence truncations are typical modifications, and C-terminally trun-
cated αS has been identified in LBs in addition to the full-length protein (Baba et al., 1998, 
Li et al., 2005, Liu et al., 2005). Interestingly, both multiplication and PD-associated point 
mutations have been implicated in altering αS aggregation (Chartier-Harlin et al., 2004, 
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Conway et al., 1998). Strikingly, an increased protein expression as caused by a triplica-
tion of SNCA is enough to cause an imbalance of the regulatory pathways and thereby 
shifting the equilibrium towards an increase in the accumulation of insoluble αS (Chartier-
Harlin et al., 2004). On the other hand, SNCA mutations have been shown to affect the 
aggregation kinetics of the protein in vitro (Conway et al., 1998, Giasson et al., 1999, Narhi 
et al., 1999, Li et al., 2001). While the two mutations A53T and E46K have been shown to 
enhance the formation of mature fibrils, the A30P mutant significantly slows down the fibril-
lization rate (Li et al., 2002, Li et al., 2001). On the other hand, A30P does form oligomers 
more rapidly than the wt protein (Conway et al., 2000b). 
 
1.2.3   Mouse models of human synucleinopathy 
By today, numerous transgenic mouse models have been developed to investigate the 
physiological and pathological role of αS in vivo. To model PD in mice, the identification of 
disease-associated mutations in αS has played a significant role. For instance, two auto-
somal dominant mutations in αS, A53T (Polymeropoulos et al., 1997) and A30P (Krüger et 
al., 1998), were found to cause early-onset FPD. In addition to αS gene overexpression, 
models expressing either A53T or A30P mutant human αS under various promoters are 
commonly used (summarized in Crabtree and Zhang, 2012). Even though none of these 
models exhibit dopaminergic cell loss in the substantia nigra, they have been proven a 
valuable tool to study the pathophysiology of synucleinopathies recapitulating neuronal αS 
pathology as seen in humans (Matsuoka et al., 2001, Kahle, 2007). In the following, three 
transgenic mouse models of synucleinopathy that were used in this thesis are described. 
 
1.2.3.1   Tg-[A30P]αS 
The first transgenic mouse line making use of a PD-linked αS mutation was the Tg-
[A30P]αS (Kahle et al., 2000a, 2000b). This model has the transgene expressing the A30P 
mutant of human αS under the control of the brain neuron-specific murine Thy-1 promoter. 
In homozygotes, the expression level of the transgene has been described to be two-fold 
higher relative to the endogenous αS level (Kahle et al., 2000a). Lewy like pathology of 
hyperphospho- and proteinase K-resistant αS inclusions are observed predominantely in 
the brainstem and spinal cord. Despite the widespread transgenic expression of αS 
throughout the brain, there is no proteinase K-resistant αS in the substantia nigra or stria-
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tum. Homozygous Tg-[A30P]αS mice further display a progressive locomotor impairment 
in the second year of life (Neumann et al., 2002). The motor phenotype is characterized by 
a hunchback posture and spastic paralysis of the hind limbs. By contrast, hemizygotes 
develop the same pathology at least 1 year later than homozygous Tg-[A30P]αS mice 
(Neumann et al., 2002). 
 
1.2.3.2   Tg-9813[A53T]αS 
The Tg-9813[A53T]αS mouse line expresses the human αS transgene harboring the A53T 
point mutation under the control of the brain neuron-specific murine Thy-1 promoter (van 
der Putten et al., 2000). This line was generated on a C57Bl/6 background and expresses 
the transgene heterozygously. These mice show an early onset of disease between 2-6 
months of age with dramatic decline of motor function. Most of the pathological changes 
are found in the spinal cord with a pronounced degeneration of motor neurons. On the 
other hand, the nigrostriatal system is not affected, athough ubiquitin-positve αS inclusions 
are also observed in the telencephalon, brainstem, and cerebellum (van der Putten et al., 
2000).  
 
1.2.3.3   Tg-M83[A53T]αS 
The third mouse model, Tg-M83[A53T]αS, harbors also the A53T mutation in the human 
αS transgene (Giasson et al., 2002). However, in these mice the transgene is under the 
control of the mouse prion promoter (Prnp). The transgenic over-expression is stated to be 
2.5- to 30-fold relative to the endogenous αS level, depending on the brain region. In con-
trast to the other two lines, this model was generated on a C57Bl/C3H mixed background. 
In homozygous mice, the motor phenotype occurs at middle age and manifests in a 
hunched back, freezing behavior and a (fatal) paralysis in all four limbs. Hemizygous ani-
mals develop a similar phenotype, however, the onset occurs in late-life (>22 months). A 
high density of αS inclusions are found in the spinal cord, brainstem, cerebellum (except 
granular and Purkinje cells), thalamus, and striatum. In addition, pronounced astrogliosis is 
observed in affected areas. In homozygous mice the pathology is reported to occur at 7 
months of age. 
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1.2   Prion-like seeding of α-synuclein aggregation 
1.2.1   The prion principle 
The best known examples of protein misfolding within the nervous system are the trans-
missible spongiform encephalopathies (TSE) (Collins et al., 2004, Aguzzi et al., 2008a, 
Prusiner, 1998). TSEs, or prion diseases, are a group of fatal degenerative disorders af-
fecting the central nervous system (CNS) in many mammals (Collins et al, 2004). Prion 
diseases include scrapie in sheep and goat, bovine spongiform encephalopathy (BSE) in 
cattle, and Creutzfeldt-Jakob disease (CJD) in humans. It was in the 1960s when scien-
tists led by D. C. Gajdusek, C. J. Gibbs, and M. Alpers were able to transmit experimental-
ly kuru (a human type of TSE) to apes and disclosed the infectious nature of a human 
brain disorder (Gajdusek et al, 1966, Alpers, 2007). Fifteen years later, S. B. Prusiner and 
colleagues proposed the composite term prion – from “proteinaceous” and “infectious” – to 
describe the causative agent for scrapie (Prusiner, 1982a). 
 
                           
Figure 4. Model of nucleation-dependent fibrillization mechanism. The re- or misfolding (step 1) of a 
native protein (sphere) into its abnormally folded isoform (cube) is a stochastic event (2) since the 
abnormal form is either unstable or sensitive to clearance and therefore unfavourable. The abnor-
mal form interacts with the native proteins and binds them by conformational conversion (3). There-
fore, the formation of a stable nucleus (4) is a time-dependent process (corresponding to the lag 
time of the orange curve). Once a nucleus (or “seed”) has formed, the protein aggregate can grow 
by incorporating monomeric protein (6) until a steady state is reached (7). However, the growing 
fibril may break into smaller fragments that further act as seeds (5) and thusly, accelerate the rate of 
fibrillization substantially (purple curve). (After Naiki and Geiyo, 1999.) 
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Despite the clinical and pathological heterogeneity, all prion diseases share a unifying 
mechanism of pathogenesis following the “protein-only” hypothesis (see Fig. 4). Central to 
TSE pathogenesis is the conformational transformation (i.e. “misfolding”) of normal, cellu-
lar PrP (PrPC) into a disease-associated, β-sheet-rich scrapie isoform of PrP, known as 
PrPSc (Prusiner, 1998, Cohen and Prusiner, 1998). Once generated, PrPSc acts as a tem-
plate to promote the conversion of PrPC into nascent PrPSc (Prusiner, 1998). As a result of 
this self-perpetuating mechanism, the pathology spreads throughout the brain, neurons 
degenerate and the disease progression sustains (Prusiner, 2013). Although PrPC and 
PrPSc share the same amino acid sequence, they differ from each other in several facets. 
Unlike PrPC, PrPSc is insoluble, partially resistant to proteinase digestion and presents 
some unconventional properties, such as resistance to high temperatures, formaldehyde 
fixation, or UV-irradation (Cohen and Prusiner, 1998, Aguzzi et al., 2008b). Moreover, 
PrPSc has been shown to adopt a wide range of structurally different morphologies. These 
‘strains’ arise from alternative conformations of the same protein and are the molecular 
basis of the phenotypic variability observed in TSEs (Morales et al., 2007, Aguzzi et al., 
2007, Cobb and Surewicz, 2009). Prion strains can be classified by different parameters. 
In transmission experiments, prion strains consistently develop a disease with distinct in-
cubation times after inoculation, clinical signs, distribution of brain pathology, and severity 
of spongiosis in the brain of affected animals (Aguzzi et al., 2007, Collinge and Clarke, 
2007). Most importantly, these characteristics are stably and faithfully propagated in serial 
passages. Although the novel principle underlying protein aggregation and disease propa-
gation was initially discovered in prion diseases (a rather “exotic” subset of degenerative 
diseases), it soon emerged that other age-related neurodegenerative disorders – including 
AD and PD – might share the same biological concept for disease pathogenesis (Prusiner, 
2012, Walker and Jucker, 2015). In stark contrast to the infectious nature of prions, how-
ever, there is no definitive evidence to support the idea for a person-to-person transmis-
sion of PD (or other proteinopathies). Therefore, to encompass all other degenerative dis-
eases it has been proposed that the term prion should be redefined (Walker and Jucker, 
2015). 
 
1.2.2   Experimental seeding of synucleinopathy 
The first evidence suggesting that αS pathology can propagate from cell-to-cell in a prion-
like manner emerged from two studies on postmortem brain tissue from PD patients who 
had previously received fetal mesencephalic tissue transplants one to two decades before 
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their death (Kordower et al., 2008, Li et al., 2008). Surprisingly, some of these nigral tissue 
grafts showed Lewy body-like pathology similar to that in the host brain. Hence, it is con-
ceivable that aggregated αS transferred from host-to-graft, where it seeded the aggrega-
tion of soluble αS. Likewise, the previously described staging of neuropathology in PD 
brains, according to which αS lesions spread to interconnected brain regions following 
anatomical pathways, is reminiscent of a prion-like mechanism of disease propagation 
(reviewed in Visanji et al., 2013). To test the hypothesis of prion-like seeding, researchers 
have performed transmission experiments, injecting misfolded proteins into the brains of 
rodents. The first experimental transmission of non-prion diseases was demonstrated in tg 
mouse models for cerebral β-amyloidosis (Meyer-Luehmann et al., 2006) and tauopathy 
(Clavaguera et al., 2009). In 2011, Mougenot and colleagues reported the experimental 
induction of synucleinopathy in αS tg mice by intracerebral inoculation with brain homoge-
nates derived from old and sick tg animals (Mougenot et al., 2012). In line with the model 
for seed-dependent fibrillization (see Fig. 4), the exogenous induction led to an accelerat-
ed onset of neurological symptoms and a reduced survival compared with that of uninocu-
lated tg controls. Moreover, subsequent work could demonstrate that exogenously induced 
αS pathology propagates within the CNS from the site of injection to interconnected re-
gions far beyond (Luk et al., 2012a). Also, it was shown that synthetic fibrils assembled 
from recombinant human αS alone are sufficient to induce Lewy-like pathology that ulti-
mately leads to a fatal neurological phenotype in mice, whereas αS-/- mice inoculated with 
αS aggregate-containing extract were resistant to the disease (Luk et al., 2012a). Thus, 
these findings are consistent with the protein-only hypothesis of prion-like disorders. How-
ever, despite several similarities between the prion protein and αS, there is no evidence 
that synucleinopathy is contagious except in experimental paradigms. 
Taken together, evidence is mounting that the prion-like spread of misfolded αS proteins 
are the cause of synucleinopathies like PD. However, this mechanism is still not fully un-
derstood and remains subject to debate. If it holds true that αS plays a central role in the 
pathological process then therapies should be targeted at stopping the aggregation in or-
der to slow down or prevent the disease progression. Therefore, understanding the patho-
genesis of the disease at the cellular and molecular levels is critical for discovering, devel-
oping, and implementing methods to improve PD treatment. 
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2  Material and Methods 
2.1   Animals 
Transgenic mice were used from the following lines: Tg-[A30P]αS (Kahle et al., 2000a, 
Neumann et al., 2002), Tg-M83[A53T]αS (Giasson et al., 2002), and Tg-9813[A53T]αS 
(van der Putten et al., 2000). Tg-[A30P]αS mice, which express human αS with the A30P 
mutation under the control of the mouse Thy1-promoter, were kindly provided by Prof. P.J. 
Kahle (University of Tübingen). Homozygous Tg-[A30P]αS mice developed a severe and 
fatal motor phenotype spontaneously with a late-onset of disease (18±2 months), whereas 
heterozygous animals did not show any motor signs by the age of 18 months. Tg-
M83[A53T]αS mice, which express human αS with the A53T mutation under the control of 
the mouse prion protein promoter, were purchased from The Jackson Laboratory. Homo-
zygous Tg-M83[A53T]αS mice developed spontaneously a very rapid disease phenotype 
terminating in a complete paralysis of both fore and hind limbs by mid-life (14±3 months). 
On the other hand, heterozygous Tg-M83[A53T]αS mice did not show any signs of neuro-
logical dysfunction by the age of 24 months. Tg-9813[A53T]αS mice, which express hu-
man αS with the A53T mutation under the control of the mouse Thy1-promoter, were gra-
ciously provided by Dr. D.R. Shimshek (Novartis). Heterozygous Tg-9813[A53T]αS mice 
developed a severe and fatal motor phenotype spontaneously at an early age (7±1 
months). A score sheet with a grading scale was used to evaluate the occurrence of motor 
symptoms in these mice. Moreover, changes in body weight were used as clinical parame-
ters to define the humane endpoints (i.e. loss of >20% of the initial weight). Initially, the 
mice showed a disturbance in balance and gait, culminating in ataxia. As the movements 
became slower, tremor and rigidity were often seen. At the end-stage of the illness, partial 
paralysis of hind limbs occurred. With the appearance of the first clinical symptoms, mice 
were provided with wet food pellets in the cage. All mice were kept under specific patho-
gen-free conditions and maintained on a 12 h light/dark cycle with food and water ad libi-
tum. The experimental procedures were undertaken in compliance with the veterinary of-
fice regulations of Baden-Württemberg (Germany) and approved by the local Animal Care 
and Use Committees. 
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2.2   CSF collection 
CSF collection was done as described previously (Maia et al., 2015) with modifications. In 
short, after anesthetizing the mice with a mixture of ketamine (100 mg/kg body weight) and 
xylazine (10 mg/kg body weight) in saline, CSF was immediately harvested from the cis-
terna magna. On average, 15-20 µl CSF were collected. CSF samples were then centri-
fuged at 2’000 x g for 10 min, assessed macroscopically for blood contamination, aliquoted, 
and stored at -80°C until further use. 
 
2.3   Injection material 
2.3.1   Brain tissue extracts 
The A30P and A53T extracts were prepared from brainstems of spontaneously ill Tg-
[A30P]αS mice (17-20 months) and Tg-9813[A53T]αS mice (6-8 months), respectively. 
After removal of the forebrain and cerebellum, the brainstems were immediately fresh-
frozen on dry ice and stored at -80°C until use. Tissue was then homogenized (Precel-
lys®24, bertin Technologies, France) to 10% (w/v) in sterile, phosphate-buffered saline 
(PBS, Lonza, Switzerland), vortexed and centrifuged at 3’000 x g for 5 min. The superna-
tant was aliquoted and immediately frozen. In addition, the A30P extract was diluted to 
1:2.5 and 1:28 in PBS. Extracts were not sonicated before inoculation unless indicated 
otherwise. The non-tg extract was derived from aged C57BL/6J (24-26 months old). Ex-
tracts were prepared as described previously (Meyer-Luehmann et al., 2006, Eisele et al., 
2009). The M83 extract was kindly provided by Dr. Thierry Baron (ANSES, Lyon Laborato-
ry) (Mougenot et al., 2012). 
 
2.3.2   Ultracentrifugation of the brain extract 
Brain extracts were thawed on ice and centrifuged at 100’000 x g for 1 h at 4°C (Beckman 
Centrifuge). The Supernatant was then transferred to a new tube, and the intermediate 
fraction at the interface to the pellet was discarded. The pellet was resuspended in sterile 
PBS using a 1ml syringe to obtain the same volume as the supernatant. Samples were 
stored on ice until use. (For more details see Langer et al., 2011, Fritschi et al., 2014b) 
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2.4   Inoculations with brain extracts and CSF 
Young (2-4-months-old) mice were anaesthetized with a mixture of ketamine (100 mg/kg 
body weight) and xylazine (10 mg/kg body weight) in saline and administered carprofen (5 
mg/kg body weight) prior to surgery. Stereotactic injections were performed manually with 
a Hamilton syringe bilateral (2.5 µl of brain extract/CSF per side) into the DG of the hippo-
campal formation (AP -2.5mm, ML ±2.0mm, DV -1.8mm) of homozygous Tg-[A30P]αS, 
heterozygous Tg-9813[A53T]αS, and homozygous Tg-M83[A53T]αS mice or unilateral (1 
µl) into the brainstem (AP -4.0 mm, ML +1.0 mm, DV -3.5 mm) of heterozygous Tg-
[A30P]αS and Tg-M83[A53T]αS recipients. Injection speed was 1.25 µl/min (DG) and 1 
µl/min (brainstem), respectively. The needle was kept in place for an additional 2 minutes 
before it was slowly withdrawn. The surgical area was cleaned with sterile saline, the inci-
sion was sutured, and the mice were monitored until recovery from anesthesia. Mice were 
assessed daily for routine health and checked weekly for body weight and the presence of 
signs of motor impairment. 
 
2.5   Tissue processing 
Histology. Mice were deeply anesthetized and transcardially perfused with ice-cold PBS 
for 5 min at a flow rate of 6.5 ml/min. After decapitation, the brains were removed and im-
mersion-fixed for 48 h in 4% paraformaldehyde (EMS, Hatfield, PA, USA, in PBS, w/v), 
then cryoprotected in 30% sucrose (Carl Roth, Karlsruhe, Germany, in PBS, w/v) for an 
additional 2 days. After freezing, serial, 25 µm-thick sagittal sections were cut through the 
hemisphere using a freezing-sliding microtome (SM 2000R, Leica). The sections were 
stored at -20°C in cryoprotection medium (25% glycerin [Applichem, Darmstadt, Germany, 
vol/vol] and 30% ethyleneglycol [Applichem, v/v], in PBS) until further use.  
Brain homogenates. Fresh-frozen hemibrains of previously perfused mice were homoge-
nized (Precellys®24) to 10% (w/v) in RIPA buffer (50 mM Tris-HCl [Sigma-Aldrich, Stein-
heim, Germany], 1% NP-40 [Merck Chemicals, Merck Chemicals, Darmstadt, Germany, 
v/v], 0.5% sodium-deoxycholate [Sigma-Aldrich, v/v], 0.1% sodium dodecyl sulfate [Sigma-
Aldrich, w/v], 150 mM NaCl [Merck Chemicals], 5 mM ethylenediaminetetraacetic acid 
[Sigma-Aldrich], pH 8.0]) with protease and phosphatase inhibitors (EDTA-free, Pierce 
Protease and Phosphatase Inhibitor Mini Tablets, ThermoFisher Scientific, Rockford, IL, 
USA), and phenylmethylsulfonyl fluoride (Sigma-Aldrich, final concentration: 1mM). Sub-
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sequently, samples were centrifuged at 1’000 x g for 5 min at 4°C and the supernatant was 
collected, aliquoted, and stored at -80°C until use. 
 
2.6   Histology 
2.6.1   Neuropathological assessment 
IHC. The fixed brain sections were washed with 0.1 M Tris-buffered saline (TBS, 50 mM 
Tris-HCl [Sigma-Aldrich], 150 mM NaCl [Merck Chemicals], pH 7.4) and mounted on mi-
croscopic glass slides (SuperFrost Plus, R. Langenbrinck, Emmendingen, Germany). After 
drying, the sections were treated with 0.3% H2O2 (Applichem, in TBS, vol/vol) for 30 min to 
block the endogenous peroxidase, antigenity was enhanced by boiling the sections in 10 
mM citrate buffer (1.8 mM citric acid [Applichem], 8.2 mM trisodium citrate [Applichem], pH 
6.0) at 90°C for 35 min. Unspecific binding sites were blocked by using 5% normal goat 
serum (Invitrogen, Camarillo, CA, USA) and 0.3% Triton-X100 (Sigma-Aldrich, in TBS, 
vol/vol) for 30 min at RT. Rabbit monoclonal anti-pS129 (1:750, EP1536Y, Epitomics, 
Burlingame, CA, Germany) was applied overnight at 4oC. The sections were then incubat-
ed with biotinylated goat anti-rabbit IgG (1:400, Vector laboratories, Burlingame, CA, USA) 
for 45 min at RT. Antibody binding was detected by using the avidin-biotin complex system 
(Vector Laboratories). After avidin-biotin solution was applied for 45 min, SG Blue kit (Vec-
tor laboratories) was used as the chromogenic substrate for peroxidase. A counterstaining 
was performed with 0.1% nuclear fast red (Sigma-Aldrich, in distilled water, w/v) and 5% 
aluminium sulfate solution (Merck Chemicals, in distilled water, w/v). Lastly, the sections 
were then dehydrated in a series of ethanol (50% through 100%) followed by an ethanol 
exchange by xylene before coverslipped with Pertex mounting medium (Pertex, Medite, 
Burgdorf, Germany).  
Thioflavine S. The fixed brain sections were washed with PBS and mounted on micro-
scopic glass slides (SuperFrost Plus). After drying, the sections were incubated in 1% thi-
ofalvin S (Sigma-Aldrich, in distilled water, w/v) for 5 min, followed by a differentiation in 
70% ethanol (3 x 10 min). The sections were then washed in distilled water and allowed to 
dry before coverslipping with Dako fluorescent mounting medium (Dako North America 
Inc., Carpinteria, CA, USA). 
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2.6.2   Imaging and image processing 
IHC. Bright-field imaging of stained sections was done using a Zeiss Axioplan 2 micro-
scope (Carl Zeiss, MicroImaging GmbH, Jena, Germany). Images were acquired with a 
AxioCam digital camera and a Zeiss 20X/0.5 numerical aperture (NA) objective. In addition, 
mosaic images were created from a series of single images acquired with a Zeiss 4X/0.1 
NA objective. Axio Vision 4.8 software was used for the automated image alignment and 
stitching. Image editing was done using Adobe Photoshop software 12.0.4 (Adobe Pho-
toshop CS, Berkeley, CA, USA).  
Thioflavin S. Fluorescence imaging of stained sections was done using a Zeiss Axioplan 
2 microscope with the FITC filter set (Carl Zeiss, MicroImaging GmbH, Jena, Germany). 
Image stacks were acquired with a AxioCam digital camera and a Zeiss 20X/0.5 NA objec-
tive (5 optical slices, 1.4 µm thickness). Stacked images were generated using Image J 
software (U. S. National Institutes of Health, Bethesda, Maryland, USA). Finally, the back-
ground was corrected by applying the “rolling ball” algorithm. 
 
2.7   Biochemistry 
2.7.1   Quantification of αS by immunoassay 
Prior to the measurement, brain homogenates and brain extracts were pretreated with 
formic acid (Sigma-Aldrich, final concentration: 70%), sonicated for 35 s on ice, and centri-
fuged at 25’000 x g for 1 h at 4°C. Supernatants were equilibrated in neutralization buffer 
(1 M Tris base [Sigma-Aldrich], 0.5 M Na2HPO4 [Merck Chemicals], 0.05% NaN3 [Sigma-
Aldrich, vol/vol]). In contrast, CSF samples were left untreated. 
Human αS was measured in brain homogenates, brain extracts, and CSF by electrochemi-
luminescence-linked immunoassay (Meso Scale Discovery, Gaithersburg, MD, USA). 
Commercial Human αS Singleplex Assay was used according to the manufacturer’s in-
structions. In brief, anti-αS antibody coated 96-well plates were blocked for 1 h with 1% 
bovine serum albumin (BSA in TBS, w/v) and washed three times with TBS. Samples were 
then co-incubated with the SULFO-TAG anti-αS detection antibody solution on the plate 
for 2 h. Read Buffer T (Meso Scale Discovery) was added after washing and the plate was 
measured immediately on the Sector Imager 6000. Data analysis was done using MSD® 
DISCOVERY WORKBENCH® software 2.0. All samples and calibrators were run in dupli-
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cates. Samples with a coefficient of variance (CV) over 20% were excluded from the anal-
ysis or repeated if additional material was available. Internal reference samples were used 
as a control in every plate, and the results were adjusted for inter-plate variability. 
 
2.7.2   SDS-PAGE and immunoblot analysis 
Samples were analyzed on NuPage Bis-Tris mini gels using NuPage LDS sample buffer 
and MES running buffer (Invitrogen, Carlsbad, CA, USA). For immunoblotting, samples 
were wet-blotted onto a nitrocellulose membrane, probed with anti-αS antibody clone 42 
(BD Transduction Laboratories, Franklin Lakes, NJ, USA) and anti-human αS antibody 
clone 15G7 (Enzo Life Sciences, Farmingdale, NY, USA). Visualization was performed 
with chemiluminescence using either SuperSignal West Pico (Thermo Scientific, Rockford, 
IL, USA) or ECL (Prime) Western Blotting Detection (GE Healthcare, Buckinghamshire, 
UK). 
 
2.8   Statistics 
Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, San 
Diego, CA, USA). Statistical significance was assessed using one-way ANOVA followed 
by Tukey’s post-hoc test and column statistics followed by Bonferroni’s post-hoc test. Data 
were expressed as mean ± SEM for the quantification of αS levels. For survival analysis, 
log-rank test was used. Multiple comparisons of Kaplan-Meier curves were performed with 
Bonferroni correction. Survival curves were expressed as median incubation times (days). 
Statistical significance level was set as follows: * if p < 0.05, ** if p < 0.01, *** if p < 0.001. 
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3  Results 
3.1  Seeding activity of formaldehyde-fixed α-synuclein pathogens 
This section is taken and/or adapted from the published manuscript (Schweighauser et al., 
2015). 
 
Prion proteins are durable under extreme environmental conditions, which might contribute 
to the persistent infectivity and spread within the human body (Wiggins, 2009). Experimen-
tally similar to prion diseases, synucleinopathy and β-amyloidosis can be exogenously 
induced by the intracerebral inoculation of brain extracts containing aggregated αS or Aβ, 
respectively, reminiscent of a prion-like seeding mechanism (Mougenot et al., 2012, Mey-
er-Luehmann et al., 2006). Remarkably, our lab has previously reported that extracts of 
formaldehyde-fixed brains from aged amyloid precursor protein (APP) tg mice or AD pa-
tients induces cerebral β-amyloidosis (Fritschi et al., 2014a). In contrast to Aβ seed-
inoculated APP tg mice, the exogenous induction of a synucleinopathy leads to an accel-
eration of disease and a shortening of the survival time (Mougenot et al., 2012). Given the 
astonishing findings of formaldehyde-resistant Aβ seeds, we sought to determine whether 
formaldehyde-fixed tissue from aged symptomatic αS tg mice would induce a fatal end-
stage synucleinopathy. 
 
3.1.1  De novo induction of synucleinopathy with formaldehyde-fixed αS seeds 
In a first attempt, we used Tg-9813[A53T]αS mice to assess the seeding capacity of for-
maldehyde-fixed αS seeds. For that purpose, we inoculated young, pre-symptomatic mice 
into the DG – a brain region that lacks endogenous pathology – with extract prepared from 
fixed and fresh-frozen brainstem tissue (Fig. 5). As described previously, the Tg-
9813[A53T]αS mice develop a severe and early motor phenotype spontaneously at a 
young age (van der Putten et al., 2000). Because of that, we sacrificed the mice after 30 
days and before the appearance of the first signs of neurological dysfunction. 
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Figure 5. Schematic illustra-
tion of tissue preparation 
and experimental setup in 
Tg-9813[A53T]αS mice. 
Brainstems from a sympto-
matic 8-month-old tg mouse 
and an age-matched non-tg 
donor were split and each 
half underwent either for-
maldehyde fixation or was 
immediately fresh-frozen. 
Intrahippocampal injections 
were done in young 2- to 3-
month-old Tg-9813[A53T]αS recipients. Mice were analyzed 30 days post-inoculation (dpi). 
 
When we examined the brains neuropathologically, deposits of phosphorylated αS were 
found in the DG of mice inoculated with both fixed and fresh-frozen tg extracts (Fig. 6). In 
contrast, mice injected with fixed or fresh-frozen non-tg extract did not exhibit any phos-
phorylated αS (pS129) inclusions. To investigate whether formaldehyde-fixed tissue is still 
able to induce an accelerated disease phenotype and to reproduce the results obtained in 
this first part, we repeated the experiment in a different mouse model of synucleinopathy. 
 
Figure 6. De novo induction 
of pathological αS aggre-
gates in the DG of Tg-
9813[A53T]αS mice inocu-
lated with formaldehyde-
fixed brainstem tissue from 
a spontaneously ill donor. 
Immunohistochemical anal-
ysis of DG pathology at the site of injection with an antibody against S129-phosphorylated αS 
(EP1536Y) and nuclear fast red counterstain of mice that had been injected 30 days prior with the 
respective extract (n = 2-3 per group). Scale bar 100 µm (applies to all panels). 
 
3.1.2 Pathogenicity of fixed αS seeds is preserved 
3.1.2.1  Reduced survival after seeding by fixed αS seeds     
Since Tg-9813[A53T]αS is a model of early-onset synucleinopathy, we not have been able 
to assess the putative differences in pathogenicity and survival between the seeding ex-
tracts. Therefore, we use additionally homozygous Tg-[A30P]αS mice, which do not devel-
op a progressive deterioration of locomotor function before 1 year of age (Kahle et al., 
2000a).  Young, presymptomatic mice from this line were inoculated with extract from for-
maldehyde-fixed and fresh-frozen tg brainstem and from non-tg control tissue (Fig 7).  
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Figure 7. Schematic illus-
tration of tissue preparation 
and experimental setup in 
Tg-[A30P]αS mice. Brain-
stems from a symptomatic 
20-month-old tg mouse and 
an age-matched non-tg 
donor were split and each 
half underwent either for-
maldehyde fixation or was 
immediately fresh-frozen. 
Intrahippocampal injections 
were done in asymptomatic 
4- to 6-month-old Tg-
[A30P]αS recipients. Mice were analyzed at the clinical end-stage displaying motor symptoms. 
 
First, we did a biochemical analysis of the formaldehyde-fixed and fresh-frozen extracts. 
SDS-PAGE and subsequent αS-immunoblotting of the 3’000 x g brain homogenate super-
natants revealed for the fresh-frozen tg extract the expected 14 kDa monomeric αS band 
and some higher molecular weight bands indicative for multimeric αS (Fig. 8A). On the 
other hand, the fixed tg brainstem extract revealed primarily high molecular weight bands 
indicative of cross-linking due to formaldehyde fixation. Because of this issue, it was very 
difficult to compare and estimate the amounts of αS present in both the fixed and fresh-
frozen tg extracts. In contrast to our first study, all Tg-[A30P]αS mice developed a severe 
motor syndrome and were sacrificed after the occurrence of the characteristic end-stage 
phenotype. Remarkably, both experimental groups of Tg-[A30P]αS mice inoculated with 
extracts from fixed and fresh-frozen tg brainstem revealed a significantly reduced life span 
(median incubation time [days] 238 and 164, respectively) compared to uninoculated mice 
(500; p < 0.01, log-rank test with Bonferroni correction) (Fig. 8B). Although not statistically 
significant, results indicate that the extract from the fresh-frozen material is more potent in 
inducing end-stage synucleinopathy compared to the extract from the formaldehyde-fixed 
tissue. 
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Figure 8. Reduced survival in Tg-[A30P]αS mice after inoculation with formaldehyde-fixed brain-
stem tissue from spontaneously ill donor. (A) Estimation of αS levels in 3’000 x g extracts of fixed 
and fresh-frozen brainstem tissue was done by immunoblotting. Human (h) and mouse (m) αS was 
detected using the antibodies Mc-42 (h- and mαS) and 15G7 (only hαS). 100 ng recombinant (rec) 
αS was loaded as control. (B) Kaplan-Meier curves for the appearance of clinical end-stage symp-
toms in Tg-[A30P]αS mice inoculated with extracts prepared from a fixed (red line; n = 4) and fresh-
frozen tg brainstem (purple lines; n = 3 and n = 7), a fixed non-tg brain (light green, n = 2), and 
fresh-frozen non-tg brain extract (green line; n = 7). The survival of uninoculated controls is also 
indicated (blue line; n = 12). 
 
3.1.2.2  Seed-induced formation of abundant synucleinopathy lesions 
The assessment of the pathological state of αS was done by IHC and thioflavin S labelling 
(Fig. 9). Perikaryal and neuritic inclusions containing phosphorylated αS were observed 
throughout the brainstem and spinal cord of all the ill Tg-[A30P]αS mice reflecting the end-
stage synucleinopathy (Fig. 9A, bottom panels). Furthermore, the lesions also showed 
intense thioflavin S labelling, indicating that these inclusions comprise proteins with β-
sheet-rich structures (Fig. 9B, bottom row). Neuropathological examination of the DG re-
vealed pS129-positive inclusions in the neurites and cell bodies of the granular layer of 
mice injected with extracts derived from formaldehyde-fixed and fresh-frozen tissue (Fig. 
9A, top row). On the other hand, no immunoreactivity was observed in the DG inoculated 
with the extract from fixed non-tg tissue. Moreover, the lesions in the DG induced by both 
fixed and fresh-frozen tg extract were also found to be thioflavin S-positive demonstrating 
the presence of amyloid deposits in a brain region that is devoid of endogenous pathologi-
cal changes (Fig. 9B, top row). When we assessed the level of induced αS accumulation 
in the DG on blind coded sections, we found that on average the pathology (pS129 and 
thioflavin S) in mice injected with the fresh-frozen extract was greater compared to mice 
injected with the formaldehyde-fixed extract (see Table 1). 
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Figure 9. De novo induction 
of amyloid pathology in the 
DG of homozygous Tg-
[A30P]αS mice inoculated 
with formaldehyde-fixed 
brainstem tissue from a 
spontaneously ill donor. (a) 
Immunohistochemical detec-
tion of phosphorylated αS in 
the brains of end-stage 
symptomatic Tg-[A30P]αS 
mice inoculated with either 
fixed or fresh-frozen tg 
brainstem extract, as well as 
fixed non-tg brain extract. 
DG is shown in the top pan-
els and the corresponding 
brainstem in the bottom 
panels. (b) Amyloid structure 
was visualised with thioflavin 
S. Scale bar 100 µm (applies 
to all panels). 
 
 
 
 
 
 
Table 1. Intracerebral inoculation of formaldehyde-fixed αS seeds in Tg-[A30P]αS mice. 
      
*Semi-quantitative pathological grading of pS129- and thioflavin S-positive labelling combined: –, 
none; ++, robust; +++, severe. 
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3.2  Seeding efficacy of CSF in comparison to soluble and insoluble αS species 
 
Others and we have shown that extracts of fresh-frozen brain tissue from symptomatic tg 
mice can induce a synucleinopathy in premature tg hosts (Mougenot et al., 2012, Luk et al., 
2012a, Masuda-Suzukake et al., 2013, Schweighauser et al., 2015). Following the concept 
of prion-like seeding, it is conceivable that the synucleinopathy-inducing factor is aggre-
gated αS. While the intercellular transfer of such protein aggregates is hypothesised to 
contribute to the progressive spread of Lewy pathology within the nervous system in synu-
cleinopathies such as PD, it is still unknown which αS species constitutes the seeding ca-
pacity (Recasens and Dehay, 2014). Thus, we asked ourselves whether αS seeds exist 
outside the brain parenchyma, e.g. the cerebrospinal fluid (CSF), which could provide a 
possible route of transportation for such seeds. Moreover, our lab has shown earlier that 
soluble Aβ assemblies from APP tg mice and AD brain tissue are potent Aβ seeds (Langer 
et al., 2011, Fritschi et al., 2014b). Therefore, stimulated by the Aβ findings, we wanted to 
know whether, and to what extent, soluble and insoluble brain-derived αS is capable of 
inducing synucleinopathy in vivo. 
 
3.2.1  Quantification of brain and CSF αS 
To study the in vivo seeding efficacy of CSF and soluble αS from spontaneously ill synu-
cleinopathy tg mice, we started off with the neuropathological examination and biochemi-
cal quantification of the αS levels in our donor mice for both the brain-derived seeding ex-
tracts as well as the CSF. 
 
3.2.1.1  Histopathology and brain αS levels 
First, the neuropathology and the levels of brain αS were examined in a mouse model of 
late-onset synucleinopathy at different ages. Therefore, mice from Tg-[A30P]αS line 
served both as donors as well as hosts.  
For histology, the left hemispheres of the brains from spontaneously ill Tg-[A30P]αS mice 
were stained with an antibody against pS129. The pS129-positive labelling revealed wide-
spread αS lesions in the brainstem (spinal cord, medulla, pons, midbrain) that is account-
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able for the severe motor phenotype at the clinical endpoint (Fig. 10A, sagittal brain sec-
tion with inserts). Conversely, young and middle-aged mice that were asymptomatic at the 
time of preparation showed no pS129-positive inclusions in the brainstem. 
To determine the levels of brain αS, the right hemispheres from asymptomatic and spon-
taneously ill mice were homogenised to 10% (w/v) in RIPA buffer. For a better comparison 
between the age groups, we performed a formic acid extraction prior to the measurement 
in order to solubilise all the αS protein. The levels of total human αS protein were then 
measured by electrochemiluminescent (ECL) immunoassay (Fig. 10B). We found that the 
transgenic αS levels from the 3-month-old Tg-[A30P]αS mice (~88’000 pmol/g wet brain) 
were significantly lower than in the 10-11-month-old mice (~103’000 pmol/g) and the 16-
19-month-old animals (~99’000 pmol/g). 
 
 
Figure 10. Histopathology and brain αS levels in Tg-[A30P]αS mice at different ages. (A) Immuno-
histochemical detection of pS129 αS deposits in Tg-[A30P]αS mice. Sagittal brain section of a 21-
month-old representative mouse with severe motor phenotype. For comparison, the representative 
images of the brainstems from a 3-month-old and a 11-month-old mouse that were devoid of the 
clinical symptoms are also shown. Scale bars 1’000 µm (sagittal brain section) and 100 µm (close-
up image, applies to all panels). (B) Quantification of human (h) αS levels in the brains of Tg-
[A30P]αS mice at different ages. The brain αS levels measured in animals of the youngest age 
group (n = 6) were found to be significantly lower than in the other two groups (n = 4 for both; 
ANOVA, F[2, 11] = 0.3674, p < 0.01). Differences between all the groups were analyzed using Bon-
ferroni’s post-hoc test for multiple comparisons. *p < 0.05, **p < 0.01. All data represented as group 
means ± SEM. 
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3.2.1.2  Elevated levels of αS in the CSF of diseased mice 
Next, we investigated how the levels of αS in CSF from Tg-[A30P]αS mice change with 
age. Therefore, CSF from young (3 months-old) and middle-aged (10-11 months-old) mice 
as well as from spontaneously ill animals was harvested (18-22 months-old). Since we 
could not get CSF from all the mice that were used for the quantification of brain αS levels, 
additional mice were included. Therefore, the two symptomatic age groups used for brain 
αS and CSF αS level measurement are different. The procedure of CSF collection was 
terminal and done as described previously (Maia et al., 2013). Remarkably, we found a 
dramatic increase of transgenic αS in the CSF, which coincided with the presence of se-
vere motor impairment (Fig. 11). The levels of αS in 18- to 22-month-old Tg-[A30P]αS 
mice at the end-stage increased by 17-fold in comparison to both pre-mature age groups. 
 
Figure 11. Increase of CSF αS in terminally ill Tg-[A30P]αS 
mice compared to asymptomatic controls. Quantification of 
human (h) αS levels in the CSF of Tg-[A30P]αS mice at differ-
ent ages. In both mouse models the CSF αS levels measured 
in animals at the clinical end-stage were significantly increased 
as compared to the levels measured in the CSF of asympto-
matic mice (n = 4-8 mice per group; means ± SEM; ANOVA, 
F[2, 13] = 19.30, p < 0.001). Differences between the youngest 
and all the other age groups were analyzed using Bonferroni’s 
post hoc test for multiple comparisons. **p < 0.01, ***p < 0.001. 
 
 
3.2.1.3  Level of αS in different fractions after ultracentrifugation 
Tg (“A30P”) and non-tg extracts were ultracentrifuged (100’000 x g for 1 h at 4°C) and the 
supernatant (“SN”) and pellet (“P”) fractions were obtained as described (see Material and 
Methods). The supernatant fraction corresponds to the PBS-soluble and the pellet to the 
PBS-insoluble portion of the extract. SDS-PAGE and subsequent αS-immunoblotting was 
done with samples of the supernatant and pellet fractions (Fig. 12A). In addition and for 
comparison, the initial 3’000 x g seeding extracts were also loaded. When comparing the 
monomeric αS bands at 14 kDa, we found the great majority of αS was in the supernatant 
fraction, while the pellet fraction contained only a small portion of αS. For a quantitative 
evaluation of our inocula, we additionally measured the αS protein levels of the different 
fractions by ECL ELISA (Fig. 12B). The results revealed that after ultracentrifugation of the 
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A30P seeding extract approximately 40% of αS in the supernatant and less than 4% in the 
pellet fraction remained confirming our previous findings by immunoblot (Fig. 12A).  
 
Figure 12. Biochemical analysis of αS in 
the different fractions derived from sponta-
neously ill Tg-[A30P]αS mice. (A) Estima-
tion of αS levels in SN and P fractions de-
rived from A30P and non-tg seeding ex-
tracts was done by immunoblotting. Human 
and mouse αS was detected using the 
antibody Mc-42. (B) Quantification of hu-
man (h) αS levels in formic acid-extracted 
samples of seeding extract, SN and P frac-
tions derived from Tg-[A30P]αS mice. 
 
 
 
3.2.2  Lack of pathogenicity of synucleinopathy CSF and soluble αS in vivo 
Given the increased levels of αS in the CSF of symptomatic mice, we sought to determine 
whether the CSF contains αS species that could induce an acceleration of the disease and 
a shortening of life span in tg recipients. Therefore, we performed intracerebral inocula-
tions into the DG of young, pre-symptomatic Tg-[A30P]αS mice with CSF from spontane-
ously ill donors (Fig. 13). As a negative control, we injected the hosts with CSF from age-
matched non-tg mice. 
 
                         
Figure 13. Schematic illustration of experimental setup with CSF harvesting. Intrahippocampal in-
jections in 2-month-old pre-symptomatic Tg-[A30P]αS mice with Tg-[A30P]αS-derived (“A30P”) 
CSF. Mice were prepared and analyzed at clinical end-stage displaying motor symptoms. 
 
Additionally, we wanted to investigate the synucleinopathy-inducing activity of soluble and 
insoluble αS, since extracts derived from fresh-frozen brainstem tissue of spontaneously ill 
Tg-[A30P]αS mice contain potent seeds as shown previously. In a first attempt, the super-
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natant fraction derived from A30P extract was inoculated into the DG of young, pre-
symptomatic Tg-[A30P]αS mice (Fig. 14). As a negative control, tg mice were injected with 
the supernatant fraction derived from non-tg extract. 
 
                        
Figure 14. Schematic illustration of the experimental setup with the tissue preparation to extract the 
soluble αS. The seeding extract derived from spontaneously ill Tg-[A30P]αS („A30P“) mice was 
further processed (100’000 x g for 1 h). The PBS-soluble supernatant („SN“) was then collected. 
Intrahippocampal inoculation was done in 2-3-month-old pre-symptomatic Tg-[A30P]αS mice and 
analyzed at clinical end-stage displaying motor symptoms. 
 
3.2.2.1  No difference in incubation times after seeding 
After the mice were sacrificed, we looked at the incubation times of the mice inoculated 
with CSF or supernatant fraction from Tg-[A30P]αS donors (Fig. 15). Surprisingly, synucle-
inopathy CSF-inoculated Tg-[A30P]αS mice had a median incubation period of 511 days, 
which was not different from non-tg-injected mice (515 days). Similarly, soluble fraction 
from symptomatic donor did not induce an acceleration of disease in comparison to non-tg 
supernatant (513 and 538 days, respectively). Furthermore, statistical analysis revealed 
that incubation times were not different between any of the injection groups. 
 
Figure 15. No difference in the incubation time of 
Tg-[A30P]αS mice after inoculation with CSF and 
PBS-soluble αS from spontaneously ill donors or 
non-tg controls. (A) Kaplan-Meier curves for the 
appearance of clinical end-stage symptoms in Tg-
[A30P]αS mice inoculated with CSF (solid lines) 
and 100’000 x g PBS-soluble supernatant (dotted 
lines; denoted as “SN”). Survival in Tg-[A30P]αS 
mice inoculated with CSF from symptomatic Tg-
[A30P]αS mice (blue line; n = 6) and CSF from 
age-matched non-tg donors (green line; n = 6). For 
comparison, the SN fraction of brainstems pre-
pared from symptomatic Tg-[A30P]αS mice (blue dotted line; n = 6) and brains from non-tg wildtype 
mice (green dotted line; n = 5) are shown. Multiple comparison analysis revealed that survival was 
not different between any of the injection groups. 
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3.2.2.2  No induction of αS aggregation by CSF and soluble αS 
Next, we assessed the histopathological seeding activity in the DG (i.e. the site of injec-
tion) of mice inoculated with either CSF or the supernatant fraction from spontaneously ill 
donors. Brain sections were stained with pS129-antibody and thioflavin S to reveal αS 
lesions (Fig. 16). In addition to the DG, we also checked the level of αS pathology in the 
brainstems from all the animals to confirm neuropathologically the observed clinical motor 
signs. 
 
     
Figure 16. No induction of synucleinopathy in the DG of Tg-[A30P]αS mice inoculated with CSF or 
PBS-soluble αS. (A) Immunohistochemical detection of pS129 in the DG and the brainstems of 
end-stage symptomatic Tg-[A30P]αS mice inoculated with CSF and 100’000 x g PBS-soluble su-
pernatant (SN) from symptomatic tg donors and non-tg mice. Scale bar 100 µm (applies to all pan-
els). (B) Histological labelling of amyloids with thioflavin S in the DG and the brainstem of end-stage 
symptomatic Tg-[A30P]αS mice inoculated with CSF and SN from symptomatic tg donors and non-
tg mice. Scale bar 100 µm (applies to all panels). 
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None of the brains from Tg-[A30P]αS mice injected with A30P or non-tg CSF (aged 19-23 
months and 18-23 months, respectively) induced the aggregation of αS in the DG (Fig. 16, 
top row, first and second columns). Likewise, neither A30P nor non-tg supernatant-
inoculated mice (aged 15-20 months and 18-21 months, respectively) did show neuropa-
thological changes in the DG (Fig. 16, top row, third and fourth columns). On the other 
hand, widespread αS pathology with similar amount of perinuclear inclusions and dys-
trophic neurites was observed in all the brainstems of symptomatic mice (Fig. 16, bottom 
rows). 
Table 2. Summary of intracerebral inoculations with CSF and PBS-soluble αS 
         
*Semi-quantitative pathological grading of pS129- and thioflavin S-positive labelling: –, none; +++, 
severe. 
 
3.2.3  Pathological seeding properties of insoluble αS aggregates in vivo 
Because of the (negative) results obtained from the CSF and soluble αS seeding experi-
ments and to further investigate the synucleinopathy-inducing factor, we then also inocu-
lated the PBS-insoluble αS fraction from terminally sick donors into young, pre-
symptomatic mice (Fig. 17). 
 
           
Figure 17. Schematic illustration of the experimental setup with extract preparation to obtain the 
insoluble αS. A normal seeding extract (see Material and Methods) of spontaneously ill Tg-
[A30P]αS („A30P“) mice was further processed (100'000 x g for 1 h). The Pellet („P“) was resus-
pended in PBS. Intrahippocampal inoculation was done in 2-4-month-old pre-symptomatic Tg-
[A30P]αS mice and analyzed at clinical end-stage displaying motor symptoms. 
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To compare the seeding efficacy of our fractions, we additionally diluted the original seed-
ing extract in PBS to match the αS levels with both the supernatant and the pellet fractions 
(see Fig. 12). According to the ELISA measurement, we assumed a dilution of 1:2.5 for the 
supernatant and 1:28 for the pellet fraction. Together with the pellet fraction, we inoculated 
these diluted extracts into the DG of pre-symptomatic mice. 
 
3.2.3.1   Reduced incubation time after seeding by insoluble αS seeds 
After the intracerebral inoculation of pre-symptomatic Tg-[A30P]αS mice with the PBS-
insoluble pellet fraction and the diluted seeding extracts, we analyzed the incubation times 
of the respective injection materials. 
As expected, we found that the survival time for the αS-containing insoluble fraction and 
the diluted seeding extracts were all significantly shorter when compared to the pellet frac-
tion derived from non-tg brain tissue (Fig. 18). However, we found no difference between 
the fraction containing the insoluble αS seeds and the diluted 1:28 seeding extract, where-
as the median incubation time for the diluted 1:2.5 seeding extract was significantly shorter 
than for the 1:28. 
Figure 18. Reduced incubation times in Tg-
[A30P]αS mice after inoculation with PBS-
insoluble αS. Kaplan-Meier curves for the ap-
pearance of clinical end-stage symptoms in Tg-
[A30P]αS mice inoculated with A30P P (blue 
line; median incubation time [days] 212.5; n = 6), 
1:2.5 (blue dashed line; 208; n = 8) and 1:28 
(blue dotted line; 265; n = 7) diluted A30P SE. 
As a control, non-tg P (green line; 555; n = 5) is 
also shown. p < 0.01, log-rank test with Bonfer-
roni correction. 
 
3.2.3.2 Formation of abundant synucleinopathy lesions by insoluble αS seeds 
When we analyzed the brains of the symptomatic Tg-[A30P]αS mice, we found that the 
PBS-insoluble fraction prepared from synucleinopathy brainstem tissue induced severe αS 
pathology with lots of perikaryal inclusions within the DG. By contrast, the pellet fraction 
from control tissue did not lead to αS aggregation (Fig. 19A, B, top row, first and second 
columns). Likewise, both diluted seeding extracts induced pS129- and thioflavin S-positive 
inclusions (Fig. 19A, B, top row, third and fourth columns). However, the results revealed a 
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dilution-dependent induction of αS aggregation in the DG, whereas the seeding capacity of 
the insoluble αS seeds appears to be increased (Table 3). As expected, widespread αS 
pathology with similar amount of deposits around neuronal perikarya and dystrophic neu-
rites was observed in the brainstems of all the mice. 
 
          
Figure 19. Severe induction of synucleinopathy in the DG of Tg-[A30P]αS mice inoculated with 
PBS-insoluble αS. (A) Immunohistochemical detection of pS129 in the DG (top panels) and the 
brainstem (bottom panels) of end-stage symptomatic Tg-[A30P]αS mice inoculated with insoluble 
αS (A30P P), 1:2.5 and 1:28 diluted seeding extract. As a control, non-tg pellet is also shown. Scale 
bar 100 µm (applies to all panels). (B) Histological labelling of amyloids with thioflavin S in the DG 
and the brainstem of end-stage symptomatic Tg-[A30P]αS mice inoculated with A30P, 1:2.5 and 
1:28 diluted A30P. As a control, non-tg P is also shown (see (A)). Scale bar 100 µm (applies to all 
panels). 
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Table 3. Summary of intracerebral inoculations with PBS-insoluble αS 
                        
 
*Semi-quantitative pathological grading of pS129- and thioflavin S-positive labelling: –, none; +, 
mild; ++, robust; +++, severe. 
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3.3  Cross-seeding capacities of non-homologous mutant α-synuclein seeds 
 
Data from cell-free system studies suggest that mutant-type αS fibrils exhibit structural and 
functional differences (Li et al., 2001, Yonetani et al., 2009). Therefore, we asked whether 
two common point mutations of the human αS gene, A53T (Polymeropoulos et al., 1997) 
and A30P (Krüger et al., 1998), have distinct functional characteristics in vivo. 
 
3.3.1  Exogenous cross-seeding is influenced by host 
To investigate whether mutant protein A53T and A30P αS exhibit a differential induction 
profile, we performed a cross-seeding experiment with extracts containing either of the 
aggregated mutant-type αS. Both mouse lines, Tg-M83[A53T]αS and Tg-[A30P]αS, are 
models with a delayed onset of motor symptoms and thus well suited for inoculation stud-
ies with survival time analysis. Therefore, we inoculated young presymptomatic Tg-
M83[A53T]αS and Tg-[A30P]αS mice with both M83 and A30P extract (Fig. 20). Injections 
were done bilaterally into the DG (2.5 µl per side). 
 
Figure 20. Schematic illustration of 
intrahippocampal inoculations in ho-
mozygous Tg-M83[A53T]αS and Tg-
[A30P]αS mice. (A, B) Both extracts 
containing either A53T (M83) or A30P 
mutant αS pathogens were injected 
into the hippocampus of 2-3-month-old 
presymptomatic Tg-M83[A53T]αS (A) 
or Tg-[A30P]αS mice (B). A30P* ex-
tract was derived from spontaneously 
ill Tg-[A30P]αS mice (17-19 months of 
age) with sonication. M83 extract was 
kindly provided by T. Baron (Lyon, 
France). Mice were sacrificed after 
displaying motor symptoms.  
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3.3.1.1  Both hosts can be seeded by each type of mutant αS seed 
Afterwards we incubated the mice until the occurrence of the motor symptoms. As for the 
previous studies, the time periods between the injections and the preparations served as 
readouts for the pathogenicity of the respective inoculum. We found that both αS extracts 
reduced the incubation period significantly in both lines when compared to non-tg extract 
(Fig. 21A, B). Moreover, these injection groups showed uniformly shortened incubation 
times with low intra-group variability than mice infused with non-tg extract. In Tg-
M83[A53T]αS mice, the median incubation time for M83 and A30P extracts were 147 days 
and 129.5 days, respectively (Fig 21A), whereas non-tg extract-inoculated mice had a me-
dian incubation period of 436 days (p < 0.017, log-rank test with Bonferroni correction). On 
the other hand, M83- and A30P-inoculated Tg-[A30P]αS mice had median incubation 
times of 203 days and 180 days, respectively (Fig. 21B). Tg-[A30P]αS mice infused with 
the non-tg control extract showed a median incubation period of 490 days (p < 0.017, log-
rank test with Bonferroni correction). However, in neither of the host lines the two mutant-
type αS extracts revealed a significantly different incubation period from each other.  
 
Figure 21. No difference in incubation period 
between M83 and A30P extract-injected mice. 
(A, B) Kaplan-Meier curves for the appear-
ance of clinical end-stage symptoms in Tg-
M83[A53T]αS (A) and Tg-[A30P]αS (B) mice 
inoculated with both M83- and A30P-derived 
extracts. (A) Survival of Tg-M83[A53T]αS 
inoculated with M83 (red line; 127-172 dpi; n 
= 8), A30P (blue line; 112-234 dpi; n = 8), and 
non-tg extract (green line; 275-546 dpi; n = 6). 
(B) Survival of Tg-[A30P]αS inoculated with 
A30P (blue line; 155-225 dpi; n = 11), M83 
(red line; 153-281 dpi; n = 11), and non-tg 
extract (green line; 203-612 dpi; n = 11). 
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3.3.1.2  Pattern of neuropathology is predetermined by the host 
To assess the level of induced pathology, we analyzed the DG of these mice. Immuno-
labelling of pS129 revealed both perinuclear and neuritic inclusions in the DG of Tg-
M83[A53T]αS inoculated with M83 and A30P extract (Fig. 22A, left and center columns). 
In contrast, mice injected with the control extract had no induced αS lesions in the DG (Fig. 
22A, right column). Qualitatively, there was no difference in the level of induced pathology 
between the αS extracts. Likewise, both M83- and A30P-inoculated Tg-[A30P]αS mice 
showed an equal level of seeded αS pathology in the DG, while the control extract failed to 
induce pathological lesions (Fig. 22B). The brainstems of all the mice had widespread αS 
lesions with similar amount of perikaryal and neuritic deposits (Fig. 22A, B, bottom rows).  
 
 
Figure 22. Induction of 
synucleinopathy lesions in 
the DG of both homozygous 
Tg-M83[A53T]αS and Tg-
[A30P]αS mice. (A, B) Im-
munohistochemical detec-
tion of pS129 in the DGs and 
the brainstems of end-stage 
symptomatic Tg-
M83[A53T]αS (A) and Tg-
[A30P]αS (B) mice. (A) Tg-
M83[A53T]αS inoculated 
with M83 (left column), A30P 
(center column), and non-tg 
extracts (right column). 
Scale bar 100 µm (applies to 
all panels). (B) Tg-[A30P]αS 
inoculated with A30P (left 
column), M83 (center col-
umn), and non-tg extracts 
(right column). Scale bar 100 
µm (applies to all panels). 
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3.3.2  Differential cross-seeding efficiency is revealed in inducible hosts 
Since we did not see a differential seeding effect between two αS extracts in neither of the 
mouse lines, we decided to repeat our study in less susceptible hosts. 
 
3.3.2.1  Inducible mouse models of synucleinopathy 
Both, Tg-M83[A53T]αS and Tg-[A30P]αS mice were homozygous for the transgene and 
developed a clinical motor phenotype spontaneously in late adult-hood. By contrast, hemi-
zygous Tg-M83[A53T]αS mice express lower levels of αS and do not develop a spontane-
ous synucleinopathy (Giasson et al., 2002, Watts et al., 2013). However, it has been re-
cently shown that hemizygous Tg-M83[A53T]αS mice were susceptible and succumbed to 
synucleinopathy after intracerebral inoculations with brain homogenates from MSA pa-
tients and spontaneously ill mice (Watts et al., 2013). Likewise, Tg-[A30P]αS mice that 
carry the transgene hemizygously were reported to have significantly lower αS levels than 
the homozygous mice (Neumann et al., 2002). Moreover, we found that hemizygous Tg-
[A30P]αS mice did not develop any signs of motor dysfunction until 20 months of age and 
with no hyperphosphorylated αS pathology (Fig. 23). In comparison, homozygous Tg-
[A30P]αS mice from our colony have a median survival time of 569 days (Fig. 23A). 
 
 
Figure 23. Hemizygous Tg[A30P]αS mice 
lack the endogenous αS pathology. (A) 
Kaplan-Meier curve for the appearance of 
spontaneous end-stage symptoms in homo-
zygous (solid line; 368-696 d; n = 35) and 
hemizygous (dashed line; n = 11) 
Tg[A30P]αS mice. None of the hemizygous 
mice had shown the clinical phenotype by the 
time of reporting this. (B) Immunohistochemi-
cal detection of pS129 in the brainstem of a 
spontaneously ill 19-month-old homozygous 
Tg[A30P]αS mouse and an asymptomatic 17-
month-old hemizygous Tg[A30P]αS animal. 
Scale bar 100 µm (applies to both panels). 
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To determine whether the two mutant-type αS extracts have a differential cross-seeding 
capacity, we inoculated young asymptomatic Tg-M83[A53T]αS and Tg-[A30P]αS mice 
both carrying the transgene hemizygously (Fig. 24). In contrast to the previous study, we 
injected 1µl of extract unilaterally into the brainstem. Moreover, we used mutant A53T αS 
extract that derived from spontaneously ill Tg-9813[A53T]αS mice. The mice were sacri-
ficed after the appearance of motor symptoms or other health issues. 
 
Figure 24. Schematic illustration of in-
tracerebral inoculations in hemizygous 
Tg-M83[A53T]αS and Tg-[A30P]αS 
mice. (A, B) Both extracts containing 
either A53T or A30P mutant αS patho-
gens were injected into the brainstems 
of 2-3-month-old asymptomatic Tg-
M83[A53T]αS (A) or Tg-[A30P]αS mice 
(B). A30P extract was derived from 
spontaneously ill Tg-[A30P]αS mice (18-
20 months of age). A53T extract was 
derived from spontaneously ill Tg-
9813[A53T]αS (7-9 months of age). 
Mice were sacrificed after displaying 
motor symptoms.  
 
 
 
3.3.2.2  Differential seeding capacities of mutant-type αS seeds 
As previously reported by Watts and colleagues, hemizygous Tg-M83[A53T]αS mice inoc-
ulated with A53T extract succumbed to disease and developed motor symptoms at a me-
dian incubation time of 212 days (Fig. 25A) (Watts et al., 2013). Remarkably, the median 
incubation period for A30P-inoculated Tg-M83[A53T]αS mice was with 149 days shorter 
than A53T-infused mice (Fig. 25B). Although not statistically significant, it can be assumed 
that the A30P extract tends to be more potent than the A53T extract in hemizygous Tg-
M83[A53T]αS mice, albeit more injections are needed to make an explicit statement. In 
contrast, Tg-M83[A53T]αS mice inoculated with the non-tg control inoculum did not show 
any motor impairment and were sacrificed >406 dpi. Intriguingly, all hemizygous Tg-
[A30P]αS mice injected with mutant-type αS extracts acquired the generic disease pheno-
type that is normally observed in homozygotes. While A30P-injected hemizygous Tg-
[A30P]αS mice had an median incubation time of 162 days, mice infused with A53T ex-
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tract developed the disease with a median incubation interval of 375 dpi. Statistical com-
parison of the incubation times between A30P- and A53T-extract injected mice revealed a 
significant difference (p < 0.05, log-rank test). By the time of reporting this study, mice in-
oculated with non-tg control extract were still alive (420 dpi). 
  
 
Figure 25. Significant difference in the incu-
bation period between A53T and A30P ex-
tracts in hemizygous Tg-[A30P]αS mice but 
not in Tg-M83[A53T]αS mice. (A, B) Kaplan-
Meier curves for the appearance of clinical 
end-stage symptoms in Tg-M83[A53T]αS (A) 
and Tg-[A30P]αS (B) mice inoculated with 
both A53T- and A30P-derived extracts. (A) 
Survival of hemizygous Tg-M83[A53T]αS 
inoculated with A53T (red line; 168-220 dpi; n 
= 6), A30P (blue line; 149-224 dpi; n = 6), and 
non-tg extract (green line; 406-833 dpi; n = 7). 
(B) Survival of hemizygous Tg-[A30P]αS in-
oculated with A30P (blue line; 148-174 dpi; n 
= 6), A53T (red line; 328-420 dpi; n = 7), and 
non-tg extract (green line; n = 7). At the time 
of reporting this study, all the mice injected 
with non-tg extract were still alive (420 dpi). 
 
 
 
 
 
3.3.2.3  Seeded formation of de novo αS lesions 
To investigate the level of seeded pathology in both hemizygous mouse lines, IHC against 
pS129 on brain sections was performed. IHC revealed widespread deposits of phosphory-
lated αS primarily in the brainstem of Tg-M83[A53T]αS mice inoculated with A53T extract 
(Fig. 26A). This was in line with previous observation by Watts and colleagues (Watts et al., 
2013). Similarly, mice injected with A30P extract showed pronounced αS pathology in the 
brainstem (Fig. 26B). Differences in the neuropathological pattern were not immediately 
apparent between A53T extract injected mice and hosts that received A30P extract. In 
contrast, no pS129-positive pathology was observed in Tg-M83[A53T]αS mice inoculated 
with non-tg extract. Likewise, the brainstems of hemizygous Tg-[A30P]αS mice inoculated 
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with both mutant-type αS extracts revealed abundant    phosphorylated αS lesions. At the 
time of writing this thesis, none of the mice injected with the control inoculum had been 
prepared. 
 
Figure 26. Induction of αS le-
sions in the brainstem of both 
hemizygous Tg-M83[A53T]αS 
and Tg-[A30P]αS mice. (A, B) 
Immunohistochemical detection 
of pS129 in brainstems of end-
stage symptomatic or aged hem-
izygous Tg-M83[A53T]αS (A) 
and Tg-[A30P]αS (B) mice. (A) 
Hemizygous Tg-M83[A53T]αS 
inoculated with A53T (left panel), 
A30P (center panel), and non-tg 
extracts (right panel). Scale bar 
100 µm (applies to all panels). 
(B) Hemizygous Tg-[A30P]αS 
inoculated with A30P (left panel) 
and A53T (right panel). Scale bar 
100 µm (applies to both panels). 
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4  Discussion 
Despite decades of extensive research, there is currently still no cure for PD that affects 
an estimated seven to 10 million people worldwide (www.pdf.org). Besides PD, αS aggre-
gates are characteristic for e.g. DLB and MSA; hence these diseases are commonly re-
ferred to as synucleinopathies. The progressive neurodegeneration is thought to be a re-
sult of the accumulation of misfolded αS within neurons or glial cells, while the cause for it 
remains elusive (Uversky, 2008). It is important, therefore, to understand the molecular 
basis of synucleinopathy pathogenesis to aid diagnosis and treatment. Recent reports, 
however, brought the prion concept into play to explain the underlying mechanism of the 
formation and propagation of pathogenic αS aggregates (Goedert, 2015, Walker and 
Jucker, 2015). Indeed, a prion-like acceleration of synucleinopathy has been described in 
transgenic mice following the intracerebral inoculation with brain homogenates from symp-
tomatic mice (Mougenot et al., 2012, Luk et al., 2012a) and synthetic fibrils (Luk et al., 
2012b).  
Stimulated by these findings, we aimed to further investigate the seeding properties of αS 
species. Therefore, we performed a series of inoculation experiments using different tg 
mice as both hosts and donors. In contrast to other research groups, we performed the 
inoculations into the hippocampus (unless otherwise stated), a brain region that lacks en-
dogenous pathology, is well-defined, and therefore easy to target (see Meyer-Luehmann 
et al., 2006). Moreover, it has been reported before that this region is susceptible to form 
αS aggregates upon injection with recombinant αS fibrils (Luk et al., 2012b). 
The results from our work addressed three major aspects: (1) we provide evidence for the 
durability of αS seeds with features reminiscent of prions; (2) we show that extracellular 
αS in CSF lacks in vivo seeding capacity, whereas insoluble brain αS is highly pathogenic; 
and (3) we present first indications for cross-seeding by PD-linked αS mutants with non-
homologous sequences. 
 
4.1  Formaldehyde resistant α-synuclein seeds 
Several studies have shown that prions are durable under extreme environmental condi-
tions (Wiggins, 2009). For instance, the infectivity of prions is retained even after formal-
dehyde treatment (Pattison et al., 1965, Brown et al., 1986, Zobeley et al., 1999, Flechsig 
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et al., 2001). Moreover, the unusual resistance to conventional disinfection procedures 
may contribute to their persistent infectivity (Brown et al., 1990, Taylor et al., 1994, Taylor, 
2000, Sutton et al., 2006). Likewise, it has been previously reported that prion diseases 
may in fact be transmitted via contaminated medical instruments during surgical proce-
dures (Brown et al., 2000, Hamaguchi et al., 2009, Thomas et al., 2013). However, im-
provements in the sterilization methods have led to a substantial prevention of iatrogenic 
transmission (Brown et al., 2012).  
Given the growing body of evidence suggesting a prion-like mechanism underlying neuro-
degenerative diseases such as PD or AD, concerns have been raised that iatrogenic 
transmission of pathological proteins other than prions may be possible. Therefore, we 
sought to determine whether αS seeds in brain resist the fixation by formaldehyde similar 
to prions (Schweighauser et al., 2015). Our lab has recently demonstrated that extracts 
from formaldehyde-fixed brain tissue containing aggregated Aβ from APP-tg mice or from 
AD patients retained the capacity to seed the induction of Aβ deposition when injected into 
the brains of APP-tg hosts (Fritschi et al., 2014a). Accordingly, we performed inoculations 
of formaldehyde-fixed brainstem tissue extracts of symptomatic mice into heterozygous 
mice transgenic for A53T αS under the control of the mouse Thy1 promoter (Tg-
9813[A53T]αS) (Schweighauser et al., 2015). Intrahippocampal injections led to the for-
mation of αS inclusions in the DG after 30 days. This was true for both fixed and fresh-
frozen tissue from symptomatic donors.  
Seeing a seeded induction of de novo pathology in the DG of Tg-9813[A53T]αS, we next 
assessed if formaldehyde-fixed brain tissue from spontaneously ill mice would induce fatal 
end-stage synucleinopathy. Therefore, we decided to use homozygous mice transgenic for 
A30P αS under the control of the mouse Thy1 promoter (Tg-[A30P]αS), because they de-
velop a progressive and terminal motor phenotype in late adulthood (Kahle et al., 2000a, 
Neumann et al., 2002). We demonstrated that also in Tg-[A30P]αS seeded αS aggrega-
tion occurred following the inoculation with formaldehyde-fixed tissue, albeit with a reduced 
seeding capacity in comparison to fresh-frozen tissue. Moreover, we observed an acceler-
ation of disease in Tg-[A30P]αS inoculated with formaldehyde-fixed tissue. Although a 
tendency towards a more potent acceleration of end-stage synucleinopathy in fresh-frozen 
extract-infused mice could be seen, no significant differences were observed between the 
incubation times of mice injected with extracts from fresh-frozen and fixed-frozen material.  
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In accordance with previous studies on Aβ, formaldehyde-fixed brain tissue from APP-tg 
donors had also a reduced seeding capacity compared to unfixed tissue (Fritschi et al., 
2014a). The decreased seeding activity of fixed tissue in comparison to fresh-frozen tissue 
might be a cause of a reduction in the number of seeds available due to the fixation by 
formaldehyde. Indeed, the immunoblot analysis revealed primarily multimeric αS species 
in the fixed tissue indicative of cross-linking due to fixation. Moreover, we followed a 
standardized protocol for short-term fixation (48h) that is commonly used in histology. 
Therefore, it is conceivable that a prolongation of formaldehyde treatment would further 
diminish the seeding efficacy of fixed tissue, albeit to be proven. Studies already highlight-
ed the seeding potential of fresh-frozen human brain material from for instance DLB (Ma-
suda-Suzukake et al., 2013) and MSA (Watts et al., 2013) patients. Therefore, a next step 
could be to assess the putative seeding activity of formaldehyde-fixed human brain tissue 
from synucleinopathy patients as it has already been shown for fixed AD brains (Fritschi et 
al., 2014a). Ultimately, archived formalin-fixed brain material could be exploited to further 
establish the relationship between the molecular architecture of αS lesions and individual 
pathogenesis. 
Taken together, the resistance to inactivation by formaldehyde underpins the persistent 
nature of αS seeds, which may contribute to the durability and spread within the human 
body. Although αS seeds share this remarkable feature with prion proteins, PD is not 
known to be contagious (Beekes et al., 2014). In contrast to prions, conventional methods 
for decontamination of medical devices or laboratory materials is sufficient (Thomzig et al., 
2014, Bousset et al., 2016). However, αS seeds are not innocuous and our results indicate 
that relevant precautionary measure should be taken when handling with formaldehyde 
fixed tissue. 
 
4.2.  Lack of seeding activity in synucleinopathy CSF 
To diagnose a synucleinopathy at an early stage is very challenging. Molecular disease 
biomarkers in bodily fluids such as cerebrospinal fluid (CSF) or blood that reflect the 
pathological state in the brain could, therefore, offer valuable tools in the clinical investiga-
tion of a disease (Delenclos et al., 2016). For instance, in a study reported in Neuron our 
lab has shown that neurofilament light chain (NfL) is increased in CSF (and blood), of 
mouse models of synucleinopathy (among others), whereby the NfL levels also responded 
to the experimental induction of synucleinopathy (Bacioglu et al., 2016). Therefore, NfL in 
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CSF may serve as a biomarker to monitor disease progression in at least such mouse 
models. Similar to NfL, extracellular αS has been investigated as a potential diagnostic 
biomarker for PD and related synucleinopathies, especially in the CSF (Gao et al., 2015). 
In the study presented here, we addressed whether CSF from mice with synucleinopathy 
contains pathogenic αS species. In this part of the thesis, we first found elevated levels of 
αS in the CSF of Tg-[A30P]αS mice, a model of late-onset synucleinopathy. Similarly to 
NfL, the increase in CSF αS coincided with the occurrence of clinicopathological features 
of synucleinopathy, while the CSF levels were unchanged in the asymptomatic states. 
Moreover, we found an increase in CSF αS after the exogenous induction of αS lesions in 
premature tg mice (data not shown). For NfL, the increase in CSF is thought to be a result 
of axonal damage associated with αS pathology in the spinal cord (Bacioglu et al., 2016). 
Likewise, in Tg-[A30P]αS neurodegeneration has been described to occur throughout the 
spinal cord (Neumann et al., 2002). Therefore, it is conceivable that elevated levels of CSF 
αS (like NfL) might be due to secondary impacts on spinal cord neurons, even though this 
remains to be shown. 
Seeing an increase in CSF αS levels, we next sought to assess the in vivo seeding effica-
cy of CSF. However, inoculation studies revealed no seeding activity of CSF from sponta-
neously ill Tg-[A30P]αS mice or non-tg controls. One reason for this could be the compa-
rable low concentrations of αS in the CSF. A reference seeding extract contains approxi-
mately 40 times more transgenic αS than CSF from spontaneously ill mice. A further rea-
son may also be found in the sensitivity of our in vivo seeding assay, which might fail to 
detect putative seeds at such low concentrations. However, this is contradicted by prelimi-
nary data which indicate that 55-fold diluted seeding extract derived from brains of sponta-
neously ill donors was still able to induce synucleinopathy, albeit with reduced seeding 
capacity (not shown). In a study published by our group, CSF from both APP-tg mice and 
AD patients also failed to induce amyloid deposition, even though the total Aβ concentra-
tion was orders of magnitude greater than the estimated titer (Fritschi et al., 2014b). We 
can only speculate, for instance, that protease digestion of αS in CSF may reduce the 
seeding effect to such an extent that the activity is abolished. In line with our findings, a 
recent study also provided evidence that extracellular αS is present in the CNS in vivo 
(Danzer et al., 2012). Furthermore, it has been shown that CSF exosomal αS species from 
patients with PD and DLB induced oligomerization of αS in vitro (Stuendl et al., 2016). 
However,,it would be interesting to know, whether these isolated exosomal αS species 
also confer seeding activity in animal models. Conversely, it might be worthwhile to test 
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the seeding potential of mouse-derived synucleinopathy CSF in an in vitro assay to cir-
cumvent the problem of sensitivity. Thus, further experiments are needed before final con-
clusion about the seeding capacity of CSF αS can be drawn. 
In order to define whether soluble αS species is seeding active, we additionally inoculated 
the 100’000 x g supernatant fraction of brain-derived seeding extracts (according to Lang-
er et al., 2011). Quantification of the transgenic αS levels prior to the injection revealed a 
2.5-fold difference between the initial tg seeding extract and the supernatant fraction 
(equal to 40% of total αS). Similar to CSF, we found that both PBS-soluble fractions de-
rived from tg or non-tg extracts failed to induce αS lesions. To exclude the possibility that 
the lower amount of αS in the soluble fraction was responsible for the negative result, we 
also assessed the seeding capacity of 1:2.5 diluted seeding extract. By contrast, we found 
that the diluted extract induced an accelerated disease phenotype with robust αS deposi-
tion. Taken together, these results suggest that the PBS-soluble fraction of a brain-derived 
seeding extract lacks an in vivo seeding activity, which cannot be explained by the lower 
concentration of transgenic αS present in this fraction. In contrast to αS, previous findings 
from our lab revealed that the β-amyloid-inducing factor is partially soluble (Langer et al., 
2011). Moreover, soluble Aβ assemblies in brain extracts were found to be disproportion-
ately highly potent in inducing β-amyloidosis. And to a further extent, a more recent study 
could demonstrate that the soluble AD brain fraction contains highly active Aβ seeds 
(Fritschi et al., 2014b). Thus, these findings highlight some remarkable differences be-
tween two proteopathic particles. 
Apart from the supernatant fractions, we also collected the pellets after the 100’000 x g 
centrifugation of tg and non-tg seeding extracts, which then were recovered by resuspen-
sion in PBS to match the volume of the supernatants. ELISA measurements of the tg pellet 
fraction revealed a concentration of αS that was 28 times lower than in the initial seeding 
extract, which corresponds to less than 4% of total αS. One point worthy of note, however, 
is the loss of αS after the ultracentrifugation. As a matter of fact, less than 50% of total αS 
remained together in the supernatant and pellet fractions. The reason for this might be the 
procedure of retrieving both fractions. In order to not “contaminate” the soluble fraction 
with pellet, the supernatant was not collected entirely leaving a small volume behind. This 
remaining supernatant at the interface was then collected and discarded whereby some of 
the pellet was included. However, this procedure ensured us to end up with “clean” frac-
tions. 
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Given the inert seeding activity of PBS-soluble αS, we asked whether and to what extent 
insoluble αS is capable of inducing synucleinopathy in tg mice despite the low amounts of 
αS. Strikingly, we found that insoluble αS derived from tg seeding extract induced pro-
nounced αS lesions. Moreover, mice injected with the pellet fraction showed a reduced 
survival time compared to control injected animals. For comparison, we additionally in-
fused mice with seeding extract that was diluted 1:28 in PBS to match with the amounts of 
αS present in the insoluble fraction. Results revealed for the 1:28 diluted extract a mild 
induction of synucleinopathy with a reduced incubation time that was less prominent than 
in pellet-inoculated mice. These data suggest that brain-derived PBS-insoluble αS from 
spontaneously ill mice contains seeding active species and is in line with two recent stud-
ies (Masuda-Suzukake et al., 2013, Recasens et al., 2014a). In one study from 2013, re-
searchers assessed whether inoculation of insoluble αS from brains with DLB can induce 
αS pathology in wt mice (Masuda-Suzukake et al., 2013). Most strikingly, DLB-derived 
sarkosyl-insoluble αS induced synucleinopathy lesions in 50% of the recipients. Moreover, 
mice injected with recombinant αS fibrils developed abundant Lewy-like pathology, where-
as mice infused with soluble αS did not. A second study demonstrated that mice inoculat-
ed with PD-derived LB-enriched fractions displayed neuronal αS inclusions. While on the 
other hand, in control animals that received non-LB fractions from the same patients, there 
was no pathological change apparent (Recasens et al., 2014a). In contrast, however, a 
recent publication demonstrated that intracerebral inoculation of both fractions of human 
LBD brain homogenate induced disease-associated deposits in CNS of mice (Jones et al., 
2015). The authors assume that the addition of protease inhibitor preserved the seeding 
capacity of the soluble fraction since soluble αS is more vulnerable to protease digestion 
than insoluble αS. However, it remains to be shown how far this would relate to our brain-
derived soluble fraction.  
When we compared the 1:2.5 and 1:28 diluted extracts we found a concentration-
dependent decrease in seeding efficiency. Moreover, the analysis of an additional dilution 
(1:55) is ongoing. However, further inoculations of diluted seeding extracts are needed to 
find conclusive evidence. Moreover, it would be of great interest to know the highest dilu-
tion factor that is still able to induce synucleinopathy. For instance, the in vivo end-point 
dilution titration is a traditional method in prion research that could be used in mice to ob-
tain a quantitative estimate of the αS pathogenicity titer (see Prusiner et al., 1982b). 
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In summary, these results revealed some interesting characteristics of pathological αS. 
Our data indicate that extracellular αS in CSF from synucleinopathy mice lacks in vivo 
seeding activity. In line with this, αS pathogenicity is primarily mediated by insoluble seeds 
and not by soluble αS. Thus, CSF αS per se might not be suited for the use as a diagnos-
tic marker of disease progression. 
 
4.3.  Cross-seeding by Parkinson’s disease linked α-synuclein mutants 
Recently, it has been hypothesized that αS may behave as ‘strains’ with distinct biochemi-
cal and functional properties, providing an explanation for the diverse clinical phenotypes 
observed between the synucleinopathies in humans (Melki, 2015, Prusiner et al., 2015, 
Peelaerts and Baekelandt, 2016). Indeed, in vitro generated αS fibrils exhibit structural and 
functional characteristics, which can even be propagated in cell culture (Guo et al., 2013, 
Woerman et al., 2015) or in vivo (Peelaerts et al., 2015). However, the different αS ‘strains’ 
were generated under various solution conditions (Bousset et al., 2013, Peelaerts et al., 
2015) or through repetitive seeded fibrillization in vitro (Guo et al., 2013). 
In this part of the thesis, we focused on two common point mutations (A53T and A30P) in 
the αS gene that have been linked to early-onset FPD (Polymeropoulos et al., 1997, 
Krüger et al., 1998). The folding and aggregation of these mutant-type αS variants has 
been investigated in multiple in vitro studies (Conway et al., 1998, Conway et al., 2000a, 
Conway et al., 2000b, Li et al., 2001, Li et al., 2002, Bertoncini et al., 2005, Yonetani et al., 
2009).  
To investigate the functional consequences of mutant A53T and A30P human αS in vivo, 
we performed two sets of cross-seeding experiments. In the first set, we used extracts of 
A53T αS derived from spontaneously ill Tg-M83[A53T]αS mice (“M83”; generously provid-
ed by T. Baron, see Mougenot et al., 2012) and extracts of A30P αS prepared from brain-
stems of symptomatic Tg-[A30P]αS mice. Intrahippocampal inoculations revealed that 
both extracts led to an accelerated disease phenotype together with the formation of 
pathological αS in the DG of homozygous Tg-M83[A53T]αS and Tg-[A30P]αS mice. Re-
markably, both groups of M83- and A30P-inoculated mice had low incubation time variabil-
ity in contrast to non-tg exract-injected recipients. This is in line with previous observations 
from other research groups (Mougenot et al., 2012, Watts et al., 2013). The histopatholog-
ical changes in the DG were not perceptibly different between M83- and A30P-infused 
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mice of both lines. In contrast, it appeared that both hosts exerted a determinant part re-
garding the non-homologous cross-seeding in the corresponding recipient (i.e. A30P in Tg-
M83[A53T]αS and M83 in Tg-[A30P]αS). In fact, the high expression levels of transgenic 
αS in homozygous Tg-M83[A53T]αS and Tg-[A30P]αS mice results in a severe and pro-
gressive motor phenotype that occurs independent of an exogenous seeding event. Since 
the (cross-) seeding appeared to be equally efficient regardless of a sequence homology 
between seed and monomeric protein, we speculate that this might be due to the high 
abundance of transgenic αS in the recipient mice. 
To test this hypothesis, we repeated the experiment but this time with hemizygous Tg-
M83[A53T]αS and Tg-[A30P]αS mice. The levels of overexpression in both hemizygotes 
were reported to be about half the levels of the regarding homozygous Tg-M83[A53T]αS 
and Tg-[A30P]αS mice (Giasson et al., 2002, Neumann et al., 2002), whereby hemizy-
gotes from both lines do not spontaneously develop a neurological disease. Consequently, 
the inoculations were done directly into the brainstem.  
Our inoculation experiment showed that both mutant-type αS variants (A53T and A30P) 
were able to seed the induction of synucleinopathy in both hosts regardless of the geno-
type. Most strikingly, inoculation with A53T and A30P αS revealed differential seeding 
characteristics in both hosts. When cross-seeded with A30P αS, Tg-M83[A53T]αS mice 
succumbed to disease earlier than by homologous seeding with A53T. Although the differ-
ence was not significant, it is still a remarkable outcome. These findings are intriguing for 
two reasons. Firstly, the results presented here demonstrated that A30P was capable of 
seeding A53T αS despite the sequence dissimilarity. This is all the more astonishing be-
cause it is known from prion research that a single amino acid alteration can have dra-
matic effects on the incubation times for instance (Manson et al., 1999). Secondly, in vitro 
studies demonstrated that A30P seeds accelerated the fibrilization of monomeric wt αS 
more effectively than A53T fibrils (Yonetani et al., 2009), although in absence of seeds the 
fibrillization of monomeric A53T occurred faster than A30P (Conway et al., 1998, Yonetani 
et al., 2009). In line with this, our findings indicate that aggregated A30P has a strong 
cross-seeding effect on soluble A53T in vivo. 
The induction of synucleinopathy in hemizygous Tg-[A30P]αS mice by inoculation with 
A30P occurred rapidly, whereas cross-seeding with A53T significantly prolonged the dis-
ease incubation period. This was consistent with our previous finding, according to which 
A30P is a better seed than A53T. On the other hand, this observation could also suggest 
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that Tg-[A30P]αS mice provide a hostile environment for A53T mutant αS. Since the A30P 
mutation in human αS has been reported to accelerate oligomerization in vitro (Conway et 
al., 2000b), we can speculate, albeit to be proven, that A53T seeds encounter an in-
creased number of oligomeric A30P that could impede further aggregation by A53T. 
While our experiments demonstrated the functional consequences of two mutant αS path-
ogens in vivo, it yet remains to be shown whether these two forms of αS fulfill the molecu-
lar criteria to be identified as two ‘strains’. Therefore, experiments are ongoing to structur-
ally characterize aggregated A53T and A30P αS using novel conformation-sensitive dyes 
(described in Aslund et al., 2009). Moreover, the resistance to proteinase K digestion of 
both aggregates will help to assign a biochemical fingerprint to these αS aggregates 
(Aguzzi et al., 2007, Kuczius and Groschup, 1999, Parchi et al., 1996). And ultimately, the 
aim is to assess whether such conformational and biochemical characteristics are propa-
gated in a non-homologous host, which could provide evidence for templated conversion 
by exogenous seeds. 
Taken together, our findings indicate altered seeding characteristics of PD-associated αS 
mutants in vivo. We also showed that the level of transgenic overexpression in hosts might 
play a superordinate role for the (cross-) seeding efficacy. While it had been demonstrated 
earlier that in hemizygous Tg-M83[A53T]αS a disease can be induced by intracerebral 
inoculation with brain homogenates from either tg mice or MSA patients (Watts et al., 
2013), it was unclear whether hemizygous Tg-[A30P]αS mice would be susceptible to the 
initiation of a neurological illness. We showed that hemizygous Tg-[A30P]αS line, like Tg-
M83[A53T]αS, is an inducible model of synucleinopathy that can be used to study func-
tional characteristics of αS variants. 
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Conclusion 
Mounting evidence suggests that the pathogenesis of PD is conceptually similar to that of 
prion diseases. Nevertheless, the cellular and molecular basis of the pathogenic mecha-
nism remains poorly understood. If the prion model proves to be true, it will open up new 
strategies for diagnosis and novel disease-modifying therapies. Therefore, the aim of this 
thesis was to provide an enhanced understanding of the seeding behavior of αS by using 
different tg mouse models of synucleinopathy.  
In this thesis, we have presented results from a series of in vivo seeding experiments, 
which underlined the prion-like properties of αS. Our finding that αS seeds resist the fixa-
tion by formaldehyde, like prions and Aβ, underpins the durable nature of αS aggregates, 
which might contribute to the spread of disease pathology in the nervous system. Howev-
er, future studies should further examine the seeding capacity of archived formalin-fixed 
brain tissue from PD patients to gain further insight into the relationship between the indi-
vidual pathogenesis and the disease pathology. 
It is unclear whether diseased CSF contains synucleinopathy-inducing seeds that poten-
tially could serve as a disease biomarker of synucleinopathy. The present finding favors 
the notion that extracellular αS from CSF is not seeding active and therefore might not be 
suitable for use as a diagnostic biomarker for the disease progression. Future experiments 
should be targeted towards the identification of other biomarker candidates in bodily fluids, 
whereby the synucleinopathy CSF may still be of great value.  
Recent studies suggest that in vitro generated αS fibrils may adopt a diversity of amyloid 
conformations with corresponding functional consequences, albeit these ‘strains’ were 
synthetic and the relevance to the in vivo situation is still unknown. From the present 
study, the functional characteristics of PD-linked αS mutants became apparent. We can 
conclude from these results that tg mouse brain-derived human αS variants may indeed 
dictate differential clinicopathological consequences. Nevertheless, experiments focusing 
on the structural properties of these isoforms are needed to provide final evidence for the 
templated conversion by non-homologous seeding in vivo. 
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